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endocytosis of EGFR. The C-terminal tail of TOM1-L1 contains a novel 
clathrin-interacting motif, which is important for exogenous TOM1-L1 to rescue 
endocytosis of EGFR in TOM1-L1 knocked-down cells. These results suggest that 
EGF triggers a transient association of EGFR with TOM1-L1 to engage the endocytic 
machinery for endocytosis of the ligand-receptor complex. Moreover, TOM1-L1 
interacts with ubiquitin and ESCRT (Endosomal Sorting Complex Required for 
Transport) family proteins, such as: Hrs (Hepatocyte growth factor Receptor tyrosine 
kinase Substrate), TSG101 (Tumor Susceptibility Gene 101), STAM1/2 (Signal 
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over-expression HA-Hrs. These results suggest that TOM1-L1 could participate in the 
machinery for EGFR sorting and degradation. In addition, TOM1-L1 negatively 
 viii
regulates Ras activation upon EGF stimulation and A431 colony formation, which 






















List of Tables 
Table 1: Signaling Proteins Recruited to Preferred Docking Sites on the EGFR 
 
Table 2: Phosphatidylinositol (4,5)-bisphoate (PtdIns (4,5)P2) Binding Domains 
found in Clathrin Adaptor Proteins 
 






































List of Figures 
 
Figure 1.1 Domain Organization of EGF Receptor  
 
Figure 1.2 Domain Organization of Grb2  
 
Figure 1.3 Domain Organization of Src   
 
Figure 1.4 Clathrin Pathway  
 
Figure 1.5 EGFR Endocytic Pathways 
 
Figure 1.6 ESCRTs components                                                           
 
Figure 1.7 Domain Organization of Hrs, STAM and TSG101. 
 
Figure 1.8 TOM1-L1  
 
Figure 3.1 Endogenous TOM1-L1 is in a ~300 kDa Complex.  
 
Figure 3.2 Characterizations of TOM1-1L1 Antibodies.  
 
Figure 4.1 Tyrosine Phosphorylation of TOM1-L1 by Fyn is Required for its 
Interaction with Grb2 and PI3K p85.   
 
Figure 4.2 Tyrosine Phosphorylation of TOM1-L1 by Src at the Putative SH2 Binding  
Site.   
 
Figure 4.3 TOM1-L1 is Tyrosine Phosphorylated by EGF via a Src-Dependent 
Pathway and Important for Interaction with Grb2.  
 
Figure 4.4 TOM1-L1 is also Tyrosine Phosphorylated by PDGF and FGF via a 
Src-Dependent Pathway.  
 
Figure 5.1 EGF Stimulates Transient Association of Tyr-phosphorylated TOM1-L1 
with Activated EGFR via Grb2.   
 
Figure 5.2 Endogenous TOM1-L1 is Primarily Cytosolic.  
 
Figure 5.3 Temporal Correlation Between the Association of TOM1-L1 with Cellular 
Membranes and EGF Stimulation of A431 Cells.  
 
Figure 5.4 TOM1-L1 is Recruited to EGF Receptor-Containing Early Endosomes in 
 xi
Response to EGF.  
 
Figure 5.5 TOM1-L1 Mutants Delay Degradation of EGF and EGFR.  
 
Figure 5.6 Mutant TOM1-L1 Delayed EGF-Induced Endocytosis of EGFR.  
 
Figure 5.7 Knockdown of TOM1-L1 Delayed EGF-Induced Degradation and 
Endocytosis of EGFR. 
 
Figure 6.1 TOM1-L1 Contains a Novel Clathrin-Binding Motif.  
 
Figure 6.2 TOM1-L1’s Clathrin Binding Motif is Important for its Role in Mediating 
EGFR Endocytosis.   
 
Figure 6.3 Effects of Protein Depletion on EGFR and TfnR Endocytosis.  
 
Figure 7.1 TOM1 Family Interacts with Ubiquitin. 
 
Figure 7.2 TOM1-L1 Interacts with Hrs, STAM.   
 
Figure 7.3 Effect of Overexpression of HA-tagged Hrs on Endosomes and TOM1-L1 
Licalization Analyized by Immunoflurescence microscpy.  
 
Figure 7.4 Simultaneous Knockdown of Both TOM1-L1 and Hrs Causes a Delay in 
EGFR Greater than Knockdown of either TOM1-L1 or Hrs Alone.  
 
Figure 8.1 TOM1-L1 Inhibits the Activation of Ras upon EGF Stimulation.   
 
Figure 8.2 TOM1-L1 inhibits the Colony Formation in A431 Cells.  
 
Figure 9.1 A Proposed Model for TOM1-L1 As a Regulated Adaptor Mediating               















AP-1/2/3/4: adaptor protein-1/2/3/4  
ARF: ADP-ribosylaton factor 
ATP: adenosine 5’-triphosphate 
BLAST: Basic Local Alignment Search Tool 
BSA: bovine serum albumin 
CCP: clathrin-coated pit  
CCV: clathrin-coated vesicle  
CHC: clathrin heavy chain  
CIAP: Calf Intestinal Alkaline Phosphotase 
CME: clathrin-mediated endocytosis  
DME: Dulbecco’s modified eagles (medium) 
DMP: dimethyl pimelidate 
DTT: dithiothreitol 
DUB: deubiquitinating enzymes  
EGFR: Epidermal Growth Factor Receptor  
ENTH domain: Epsin N-terminal Homology) domain 
ErbB (EGFR): originally named because of their homology to the erythroblastoma  
            viral gene product, v-erbB 
ESCRT: Endosomal Sorting Complexes Required for Transport  
FAK: Focal Adhesion Kinase 
FGF: Fibroblast growth factor 
FITC: Fluorescein Isothiocyanate 
 xiii
GAT domain: GGA and TOM1 domain 
GDP: Guanosine Diphosphate 
GEF: Guanine Nucleotide Exchange Factor 
GGA1/2/3: Golgi-associated γ-adaptin ear homology, ARF binding protein 1/2/3 
GM1: Monosialotetrahexosylganglioside 
GPI : Glycosylphosphatidylinositol 
Grb2: Growth factor Receptor-Bound Protein 2 
GST: Glutathione-S-Transferase 
GDP: Guanosine 5’-Diphosphate 
GTP: Guanosine 5’-Triphosphate 
HA: Hemagglutinin 
HEPES: N-2-hydroethylpiperizine-N’-2-ethanesulfonic acid 
HPLC: High-Performance Liquid Chromatography 
Hrs: Hepatocyte Growth Factor-Regulated Substrate 
IF: Immunofluorescence 
IP: Immunoprecipitation 
IPTG: Isopropyl β-D-thiogalactopyranoside 
kD: kilo Dalton 
M6PR: Mannose-6-phosphate receptor  
Mab: Monoclonal antibody 
MAPK: Mitogen-Activated Protein Kinase 




mg: milligram  
MVB: Multivesicular Body 
ONPG: O-Nitrophenyl β-D-Galactopyranoside 
OD: Optical Density 
PA: Phosphatidic Acid 
PAGE: Poly-Acrylamide Gel Electrophoresis 
PCR: Polymerase Chain Reaction  
PDGF: Platelet-Derived Growth Factor 
Pfu: Pyrococcus furiosus 
PKC: Protein Kinase C 
PI3K: Phosphoinositide 3-Kinase 
PIP3: Phosphatidylinositol-3,4,5-trisphosphate 
PLCγ: Phospholipase C-γ 
PLD: Phospholipidase D 
PM: Plasma Membrane 
PMSF: Phenyl-Methyl-Sulfanyl Fluoride 
PI4,5P2: Phosphatidylinositol 4,5-bisphosphate 
PTB domain: Phosphotyrosine-Binding domain 
PtdIns3P: PtdIns-3-phosphate  
PTK: Protein Tyrosine Kinase 
PVC: Pre-Vacuolar Compartment 
 xv
PX: Phox (homology domain) 
Ras: Rat Sarcoma 
RNAi: RNA interference 
RPMI: Roswell Park Memorial Institute 
RTK: Receptor Tyrosine Kinase 
SDS: Sodium Dodecyl Sulfate 
SFK: Src Family Kianses 
siRNA: small interference RNA 
SH2 domain: Src Homology 2 domain 
SH3 domain: Src Homology 3 domain 
SNARE: SNAP Receptor 
SOS: Son of Sevenless 
SRP: Signal Recognition Particle 
STAM: Signal-Transducing Adaptor Molecule 
STAT: Signal Transducers and Activators of Transcription 
TfnR: Transferrin Receptor 
TGFα: Transforming Growth Factor-α 
TGN: Trans-Golgi Network 
TOM1: Target of the Oncogene v-myb 
TOM1-L1:TOM1-Like 1 
TSG101: Tumor Susceptibility Gene 101  
VHS domain: Vps27p, Hrs and STAM domain 
 xvi
Vps: Vacuolar Protein Sorting 
UEV domain: Ubiquitin E2 Variant domain 
UIM: Ubiquitin-Interacting Module 
XDP: Xanthine Diphosphate 















 Chapter 1  Introduction 
 
1.1 Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor (EGF) receptor is a 1186-residue (170kDa) 
transmembrane tyrosine kinase, and belongs to the HER/ErbB family (originally 
named because of their homology to the erythroblastoma viral gene product, v-erbB). 
The EGFR can be activated by 7 types of structurally related growth factors by 
transferring the γ-phosphate of bound ATP to the tyrosine residues of the exogenous 
substrates and C-terminal domains of the EGFR (in a trans-phosphorylation manner).  
 
EGFR mediates proliferation, survival, and differentiation in mammalian cells (Oda, 
et al., 2005), which ultimately activates several signaling pathways. For example, 
classical Mitogen-Activated Protein Kinase (MAPK, originally called "Extracellular 
Signal-Regulated Kinase, Erk") is activated by the appropriate adaptor or signaling 
molecules that recognize EGFR C-terminal phosphotyrosine. During this process, 
activated EGFR is also endocytosed from the plasma membrane. Some of the EGFR 
are internalized through the fast clathrin-dependent pathway, while others through the 
slow clathrin-independent pathway (Le Roy and Wrana, 2005). After internalization, 
EGFR is transported to the early endosome, sorted at the MVB (multivesicular body), 




1.1.1 EGFR Structure 
All ErbB family receptors including the EGFR compose type I transmembrane 
proteins that are glycosylated and have disulfide-bonds in their ectodomains, which 
are required for membrane location and ligand-binding. They have a single 
transmembrane domain and a large cytoplasmic region that contains a tyrosine kinase 
and multiple phosphorylation sites (Slieker et al., 1986). The structure of the mature 
EGFR (ErbB1) receptor is represented as below.  
 
 
Figure 1.1 Domain Organization of EGF Receptor. 
Abbreviations: I and III: ligand binding domains; II and IV: cysteine-rich domains; TM:  
transmembrane domain; JM: juxtamembrane domain which undergoes extensive 
co-translational (N-glycosylation) or post-translational modifications (phosphorylation and 
ubiquitination); n-lobe and c-lobe: kinase domain; CT: the carboxy-terminal terminal 
containing all known auto-phorylation sites. (Adapted from Linggi and Carpenter, 2006. ) 
 
The C-terminal domain of the EGFR contains the phosphotyrosine residues that 
modulate EGFR-mediated signal transduction. These residues are shown in Table 1. 
On the other hand, phosphorylation of the EGFR at specific serine/threonine residues 
attenuates its kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are 
phosphorylated by CaM kinase II; mutations to either of these residues upregulate 
EGFR tyrosine autokinase activity (den Hartigh et al., 1992). 
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Table 1 Signaling Proteins Recruited to Preferred Docking Sites on the EGFR 
Phosphorylation site  Effector Effector’s binding motif  
Tyr 891 c-Src SH2 
Tyr 920 c-Src SH2 
Tyr 992 PLC-γ C-SH2 
 PTB-1B  
Tyr 1068 Grb2 SH2 
Tyr 1086 Grb2 SH2 
 Dok-R  
 Abl  
Tyr 1148 Shc PTB 
 PTB-1B  
Tyr 1173 Shc PTB 
 PLC-γ N-SH2 
 SHP-1  
(Adapted from Linggi and Carpenter, 2006.)  
 
1.1.2 Dimerization and Activation 
Ligand-induced EGFR dimerization activates the tyrosine kinase domains. The 
process of dimerization is necessary, but not sufficient for its intracellular kinase 
activation (Domagala et al., 2000; Moriki et al., 2001). Data on deletion mutants have 
indicated that the ectodomain, and in particular its domains I and II, play an active 
role in preventing kinase activation. While the tyrosine kinase domain residues 
835-918 are necessary for dimerization independent of ligand, EGFR does not require 
phosphorylation of its kinase activation loop for full enzymatic activity. Ligand 
binding increases the proportion of dimerized EGFR, the reorientation of the kinase 
domains and the affinity for ATP binding. This enhanced kinase activity is likely due 
to its conformational changes (Cho et al., 2002, Humphrey et al., 1988, Yamazaki et 
al., 1988, Malden et al., 1988, Berezov et al., 2002).   
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EGFR C-terminus can be autophosphorylated on five tyrosines or 
transphosphorylated by other kinases such as Src and Jak-2. Activated EGFR interacts 
with the SH2 (Src Homology 2)  or PTB (Phosphotyrosine-Binding) domains of 
intracellular signal transducers and adaptors, causing their colocalization and the 
assembly of multicomponent signaling “particles” (Tice et al., 1999, Yamauchi et al., 
1997). SH2 or PTB domain-mediated interaction of intracellular-proteins with EGFR 
is dependent on their phosphorylation state of key tyrosine residues. Whereas some 
other proteins such as ZPR-1 (Zinc Finger Protein 1) and STAT (Signal Transducers 
and Activators of Transcription) transcription factors interact with EGFR in their 
unphosphorylated state and are activated or translocated to other cellular location 
upon ligand stimulation (Galcheva-Gargova et al., 1996, Xia et al., 2002, Olayioye et 
al., 1999).  
 
 
The C-terminal truncated EGFR alone is enough to stimulate the normal EGFR 
signaling pathway (Walker et al., 1998, Wong et al., 1999). Signaling proteins 
associate directly interacting with EGFR C-terminal scaffold or indirectly via adaptor 







1.1.3 Shc, Grb2 and the Ras/MAPK Pathway 
A well studied pathway activated by EGFR is the classic EGFR-Shc (Src 
Homologous and Collagen)-Grb2 (Growth Factor Receptor-bound Protein 2)- 
Ras/MAPK pathway, which starts from the proto-oncogene Ras and ends with the 
serine/threonine kinase MAPK. Grb2 is the key adaptor in this pathway (Lowenstein 
et al., 1992). Grb2 interacts with FAK, dynamin (cytoskeletal reorganization), Cbl, 
Dab-2(Disabled-2), SOCS-1(Suppressor of Cytokine Signaling proteins-1), and SHIP 
(Src Homology 2 domain-containing Inositol Phosphatase). Grb2 binds constitutively 
to the Ras exchange factor Sos (Son Of Sevenless ) and is localized to the cytosol. 
Upon EGFR stimulation and phosphorylation, Grb2 can interact with EGFR by 
binding either directly via EGFR Y1068 and Y1086 or indirectly via Shc.  
 
Shc is EGFR-associated, and tyrosine phosphorylated by EGFR (Batzer et al., 1994, 
Sasaoka et al., 1994, Sakaguchi et al., 1998, Sato et al., 2002). It contains SH2 and 
PTB domains that associate with tyrosine-phosphorylated domains such as 
MEKK-1(MAPK kinase kinase-1) and cadherin (Meisner et al., 1995, Schlaepfer et 
al., 1999, Xu et al., 1998, De Sepulveda et al., 1999, Harmer et al., 1999, Pelicci et al., 
1995, Xu et al., 1997 ). However Shc’s function is still unclear (Hashimoto et al., 
1999).  
 
The interaction of the membrane-associated Ras with Sos is increased by recruiting 
the Grb2/Sos complex to EGFR at the plasma membrane. This leads to the exchange 
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of GDP-Ras for GTP-Ras and the activation of Ras. Ras activation subsequently 
activates serine/threonine kinase Raf-1, which eventually phosphorylates, activates 
and promotes the nuclear translocation of Erk-1 (Extracellular Signal-regulated 
Kinase 1) and Erk2 (Extracellular Signal-regulated Kinase 2) via a series of the 
intermediate kinases (Di Guglielmo et al., 1994).   
  
1.1.3.1 Grb2 (Growth Factor Receptor-bound Protein 2) 
 
Figure 1.2 Domain Organization of Grb2 
Abbreviations: SH3: Src Homology 3 domain; SH2: Src Homology 2 domain 
 
Grb2 is a small 25kDa (217 aa) protein, which contains: two SH3 domains. One is at 
the N-terminal and the other is at the C-terminal, with a SH2 domain in the middle 
(Chardin et al., 1995). Two long flexible arms (or linkers) lie between the SH2 and 
C-terminal SH3 domains. Data on the X-ray crystal of Grb2 shows a rather weak 
interaction between the two SH3 domains and the flexible linker                
region. This enables the SH3 domains to associate and recognize multiple targets with 
diversely spaced proline rich motif (Downward, 1994). 
 
Grb2 interacts with phosphorylated receptors to associate RTK (Receptor Tyrosine 
Kinase) with activation of the Ras pathway. The SH3 domains of Grb2 can also bind 
directly to Cbl. In mammalian cells, Grb2 can indirectly recruit Cbl to EGFR or Met 
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receptors. Cbl can directly interact with specific residues in autophosphorylated 
receptors through its SH2 domain (Waterman et al., 2002; Peschard et al., 2003). This 
bivalent binding module may be critical for receptor-mediated phosphorylation of Cbl 
(via association with Grb2) or Cbl-induced ubiquitinations of receptors (via direct 
association of Cbl with RTKs) (Yoon et al., 1995, De Sepulveda et al., 1999). Grb2 
activates Ras/MAPK signaling pathway via Sos. On the other hand it also promotes 
the ubiquitination and endocytosis of receptors through recruiting the Cbl-CIN85 
(Cbl-interacting protein of 85 kDa)-endophilin (End) complex, and binding to Sprouty, 
SHIPs, SOCS and Ack, which further attenuates the receptor signaling pathways 
(Schlaepfer et al., 1999, Xu et al., 1998, De Sepulveda, et al., 1999, Harmer and 
DeFranco, 1999). Thus, Grb2 plays a bridging role of integrating both positive and 
negative signaling pathways. It is quite interesting to understand how the cell 
regulates such interactions. These interactions are dependent on the different affinity 
and the relative concentrations of these proteins (Damelin and Silver, 2000). 
 
1.1.3.2 The Src Family Kinase (SFK) 
 
Figure 1.3 Domain Organization of Src 
Abbreviations: M: the Membrane-binding domain; U: Unique domain; SH3: Src Homology 3 
domain; SH2: Src Homology 2 domain; L: linker; catalytic domain and R: Regulatory 
domains. (Adapted from Martin GS, 2001)  
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Src is a non-receptor tyrosine kinases of SFKs. Src family kinases consist of Fyn, Yes 
Lck, Hck, Blk, Fgr and Lyn. SFKs associate with membrane via N-terminal 
myristoylation (Okamura and Resh, 1994). Src kinase is activated in multiple ways, 
including displacement of the intramolecular interactions of certain residues, 
dephosphorylation of pY527 by a tyrosine phosphatase, or phosphorylation of Y416. Src 
can be activated by a single stimulus through more than one mechanism.  
 
The specific proline-rich motifs in Src, is the unique region that varies among SFK 
family members. SH2 domain binds to residues in the specific sequence (pYEEI) 
(Cicchetti et al., 1992, Ren et al., 1993, Feng et al., 1994, Pawson and Gish, 1992, 
Songyang et al., 1993, 1994). The kinase lies on the left of the C-termin of the 
molecule, which consists of the major autophosphorylation site (Y416 in Src) in the 
activation loop (Hunter and Cooper, 1985, Parsons and Weber, 1989, Smart et al., 
1981). A conserved tyrosine residue (Y527 in Src) that lies at the end of the C-terminal 
is essential for auto-regulation in SFKs (Brown and Cooper, 1996). For Src, the SH3 
and SH2 domains are at the back of the kinase domain. The SH2 domain binds to 
pY527 while the SH3 domain interacts with a short polyproline type II helix between 
the SH2 and kinase domains. These two interactions lock c-Src in a closed, 
inactivated state (Xu et al., 1999, Schindler et al., 1999, Young et al., 2001). Kinase 
activity is repressed by the cytoplasmic kinase Csk, which phosphorylates a tyrosine 
residue in the C-terminal tail. This repression is achieved by two mechanisms: i) 
binding of the SH2 domain to the phosphorylated C-terminal tyrosine, and ii) binding 
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of the SH3 domain to a poly-proline type II linker helix that connects the SH2 and 
kinase domains (Sicheri et al., 1997).  
 
The Src family kinases are cytosolic tyrosine kinases, and Src was reported to be 
involved in signaling pathway stimulation by polypeptide growth factor receptors 
such as EGFR (Belsches et al., 1997). Src is involved in the regulation of a variety of 
normal and oncogenic processes, such as proliferation, differentiation, survival, 
motility, and angiogenesis (Thomas et al., 1997). It also interacts with numerous 
cellular factors, such as cell surface receptors of EGF family, CSF, PDGF, FGF 
receptors, and cell-cell adhesion molecules (integrins, etc), focal adhesion kinase 
(FAK), and adaptor proteins p130Cas (Crk-associated substrate, 130 kDa) (Biscardi et 
al., 1999, Irby and Yeatman, 2000, Owens et al., 2000, Moro et al., 2002, Migliaccio 
et al., 1996, Boonyaratanakornkit et al., 2001, Luttrell and Lefkowitz, 2002, Ma et al., 
1998, Silva , 2004, Kaplan et al., 1994, Burnham  et al., 2000, Sato et al., 2002).  
 
It was observed that during the co-overexpression of both Src and EGFR in human 
breast cancer tissues and cell lines, Src activity is essential for Erb2-mediated 
anchorage-independent growth, motility, and survival (Biscardi et al., 2000, Karni et 
al., 1999, Belsches-Jablonski et al., 2001). Upon EGF stimulation, Src physically 
associates with activated receptors and is transiently activated (phosphorylated) and 
phosphorylates downstream targets, including EGFR itself on multiple sites including 
Y845 (Maa et al., 1995, Muthuswamy and Muller, 1995, Belsches-Jablonski et al., 
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2001). pY845  induces EGFR by at least two distinct signaling pathways, i) one that 
activates EGF-induced cell proliferation via STAT5b and ii) another that promotes 
cell survival via Cox II (Kloth et al., 2003, Boerner et al., 2004). In fact, EGFR is 
transactivated through Src by multiple extracellular factors including G 
protein-coupled receptors, ionizing radiation, ultraviolet light, and certain ions 
(Knebel et al., 1996, Prenzel et al., 2000, Wu et al., 2002). These data indicate that 
Src activates EGFR by coupling EGFR with other nonrelated membrane receptors and 
intracellular signaling molecules via pY845.  
 
Clathrin and dynamin which are involved in internalization of numerous membrane 
receptors (EGFR, PDGF etc) are also substrates of Src. This demonstrates that Src 
mediates the endosomal pool of activated receptors (Wilde et al., 1999, Ahn et al., 
2002). Cbl is known to be an E3 ubiquitinating enzyme for attaching multiple 
monoubiquitin moieties to the cytoplasmic domain of EGFR, a modification involved 
in endocytosis and subsequent sorting of internalized receptor to MVB (Citri and 
Yarden, 2006; Rubin et al., 2005). Src collaborates with the ubiquitination and 
proteosomal degradation of Cbl, thereby attenuating the level of Cbl and postponing 
EGFR downregulation, hence forth promoting the recycling of receptors back to the 
plasma membrane and extends EGFR signaling (Bao et al., 2000, Muthuswamy et al., 
1994, Osherov et al., 1994, Biscardi et al., 2000). Overexpression of Src drastically 
increases EGF-induced proliferation and transformation in fibroblasts and epithelial 
cells (Luttrell et al., 1988, Maa et al., 1995). Reducing Src activity by microinjection 
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of antibodies, overexpression of domain negative Src or treatment by Src-specific 
inhibitor can block EGF-dependent DNA synthesis and reverse the transformation of 
the phenotype of EGFR- or Erb2-overexpressed cells (Karni et al., 1999).  
 
In A431 and colon carcinoma cell lines that overexpress EGFR, EGF-dependent Src 
kinase activation was increased and their direct interaction was observed (Osherov et 
al., 1994, Mao et al., 1997). In vitro, Src interacts with and phosphorylates the novel 
sites Y891 and Y920 within the kinase domain of the EGFR (Stover et al., 1995).  
pY920 interacts with PI3-K p85 subunit. Y845 and Y1101 are two other Src-dependent 
phosphorylation sites. pY1101 is a potential Src-binding site, and pY845 is necessary for 
STAT5b activation. It was suggested that phosphorylation by Src may significantly 
enhance the activation of EGFR, but so far the data remains controversial (Gotoh et 
al., 1992, Tice et al., 1999).  
 
EGFR and She (Src Homology 2 domain containing E) are phosphorylated by both 
EGFR and Src at different sites, which potentially contributes to the spectrum of 
She-mediated response from EGFR (Sato et al., 1997). p120RAS GAP(GTPase 
Activating Protein) but not p190Rho GAP is specifically phosphorylated by Src, 
implying that Src is a downstream signal tranducer of EGFR. Src substrates such as 
FAK (focal adhesion kinase), p130Cas, Cortactin, EAST(Epidermal growth factor 
receptor-Associated protein with SH3- and TAM domains), and Eps-8(EGFR 
Substrate Protein-8) also mediate cytoskeletal reorganization upon stimulation of EGF 
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(Schlaepfer et al., 1999, Nojima et al., 1996, Huang et al., 1998, Lohi et al., 1998, 
Provenzano et al., 1998.). Besides the fact that Src-dependent pY920 of EGFR 
provides a docking site for Phosphoinositide 3-kinase (PI3K) p85 subunit, Src can 
also directly phosphorylate and activate PI3K (Shoelson et al., 1993).  
 
In summary, the activation of the EGF receptor is closely associated with activation of 


















Endocytosis (or uptake) is the internalization of molecules from the cell plasma 
membranes into internal membrane compartments through two main pathways: the 
classic, clathrin-mediated endocytic pathway and the non-classic, 
clathrin-independent, but lipid-raft-dependent route.  
 
1.2.1 The Classic Clathrin-dependent Endocytic Pathway 
In the classic clathrin-dependent endocytic pathway, soluble clathrin is recruited from 
the cytoplasma membrane, and the clathrin triskelia are assembled into a polygonal 
lattice at the plasma membrane to form coated pits, which buds and pinches off from 
the membrane in a dynamin-dependent manner to form clathrin-coated vesicles (CCV) 
(Figure 1.4) (Kirchhausen, 2000, Bonifacino and Lippincott-Schwartz, 2003). The 
clathrin coat grows at its edges through polymerization of clathrin to from a coated pit, 
in which receptors destined for internalization concentrate through interacting with 
adaptor proteins.  
 
In a series of geometric changes driven by protein/lipid interactions, the 
clathrin-coated pit (CCP) invaginates to form a thin membrane neck, which is severed 
through the action of the large GTPase dynamin in combination with accessory 
proteins. After scission, the receptor-laden CCV uncoats and delivers its receptor 
cargo to the endosomal system (Farsad and De Camilli, 2003, Hinshaw, 2000, Pearse 
et al., 1987). The clathrin-coated vesicles are uncoated and fused with early endosome, 
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in which some unique protein constituents such as the FYVE-domain proteins are 
recruited to endosomes through binding to phosphatidylinositol-3-phosphate 
(PtdIns3P, PI3P) that can associate with and control the activity and destination of 
proteins in these compartments. The early endosome is a key control point for sorting 
receptors, in which the receptors are either recycled back to the cell surface through 
Rab11 positive endosomes, or to the multivesicular body (MVB), late endosome and 
lysosome for degradation though the intralumenal vesicle (ILV) of multivesicular 
endosomes.  
 
Clathrin-coated vesicles (CCVs) are three-layered vesicles. The inner membrane layer 
is embedded with cargo; the middle layer consists of various clathrin-adaptor 
molecules and other proteins that play accessory/regulatory roles in CCV assembly; 
and the outer clathrin layer (Kirchhausen, et al., 1981). The clathrin layer is a 
three-dimensional array of triskelia, which consists of three 1,675-residue (about 190 
kDa) clathrin heavy chains (CHCs) and three 25-29 kDa clathrin light chains (CLCs), 
and has an approximately three-fold rotational symmetry.  
 
In the clathrin-dependent endocytotic pathway, adaptor proteins select specific cargo 
at the plasma membrane and recruit structural and regulatory components (clathrin 
and scaffolds), which help to stabilize early endocytosis protein complexes necessary 
for the formation of clathrin-coated pits (CCPs) (Owen, 2004, Traub, 2003, Wendland, 
2002). The clathrin adaptor is a protein molecule that can directly connect the purely 
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mechanical clathrin scaffold and a component of the membrane through phospholipid 
or transmembrane proteins or both simultaneously. More than 20 clathrin adaptors 
have been identified, which are composed of compact folded domains and long 
unstructured regions through which they bind to the N-terminal, 
330-residue-β-propeller terminal domains (TDs) of clathrin and also to each other. 
These interactions are almost always regulated by short, linear motifs that associate 
with a folded domain, which causes a moderate-to-weak strength of binding (Kd 
=1-100uM) with a relatively short half-life (t1/2=1-10s). Clathrin-binding adaptors 
initiate this process through direct association with clathrin and the cargo proteins, 
such as adaptor protein-2 (AP2). In spite of being cytosolic proteins, the endocytic 
adaptors are recruited specifically at the plasma membrane through the cooperation of 
interactions such as: lipid-adaptor interactions, cargo-sorting-signal-adaptor 
interactions, and accessory-protein-adaptor interactions (Table 2) (Szymkiewicz et al., 
2004, Robinson, 2004, Owen et al., 2004, Perrais et al., 2005, Meyerholz et al., 2005). 
These adaptors also interact with phospholipids, which are found in coated pits and 
facilitate vesicle formation and budding.  
 
Two hypotheses have been proposed for this endocytosis pathway: one is ‘the 
Maturation model’ whereby vesicles that are derived from the plasma membrane 
forms a de novo, temporary early endosome that matures to become a transient late 
endosome and then a degradative lysosome; another is the ‘pre-existing compartment’ 
where the early endosome and late endosome are stable compartments that are 
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connected by vesicular traffic (Murphy et al., 1991, Griffiths and Gruenberg, 1991). 
In fact, certain cargos are delivered to endosomes and lysosomes through the 
non-clathrin endocytic pathway, while they can also be targeted to other 
compartments such as the Golgi by the clathrin-dependent pathway (Gruenberg and 
Stenmark, 2004, Schlessinger et al., 2002, Bishop, 2003). 
 
Table 2 Phosphatidylinositol (4, 5)-bisphosphate (PtdIns (4,5)P2) Binding Domains 
found in Clathrin Adaptor Proteins 
 











Binding takes place between the phosphate groups of 
PtdIns(4,5)P2 and basic sidechains (mainly two clusters of 
lysine residues at each end of the binding domain) on the 
N terminus of the α subunit and a cluster of conserved 





Two α helices (α helices 1 and 2) out of the nine that 
comprise the ANTH contact the membrane. The 
interaction takes place between the solvent exposed 
sidechains of three consecutive lysine residues and one 
histidine and the head group of the lipid 
ARH, Dab2 
and Numb  
PTB domain Direct contact between basic residues in the PTB domain 
lipid-binding pocket and PtdIns(4,5)P2 
β-arrestin Arginine/lysin
e residues 
High-affinity basic PtdIns(4,5)P2 binding site at the 
C-terminal  domain of β-arrestin 
Epsin ENTH 
domain 
The ENTH domain binds both the head group and 
glycerol backbone of PtdIns(4,5)P2 in a basic pocket 
formed by the first four of the eight α helices in this 
domain. Upon binding of the ENTH domain  to the 
membrane, a new α helix forms called helix 0 (residues 
3-15), which inserts its outer hydrophobic surface into the 
hydrophobic phase of the membrane and its inner basic 
surface augments the PtdIns(4,5)P2 head group binding 























































































































































































































































































































































Clathrin-dependent endocytotic pathway is a well-characterized uptake mechanism 
for nutrients, pathogens, antigens, growth factors and receptors. Endocytic adaptors 
are important for downregulation of growth factors receptors from the plasma 
membrane. Where the receptor is bound to its ligand, it is endocytosed and can be 
transported to a degradative compartment such as lysosome. A particular adaptor also 
can deliver the receptor to new locations where distinct sets of signaling effectors can 
be activated (Polo et al., 2003). Endocytic adaptors also play a role in determining the 
post-internalization fate of the receptors (Lakadamyali et al., 2006). Different 
dynamics in different endocytotic pathway may dictate various activated signaling 
pathway, and these specific adaptors direct these post-internalization decisions.  
 
1.2.2 The Non-classic Clathrin-independent Endocytosis Pathway  
Although the machinery of non-classic clathrin-independent endocytosis pathways are 
still not well characterized, data implies that it is lipid raft-dependent (Parton et al., 
2004, Nichols, 2003a,b, Sato et al., 2004). The lipid raft-resident protein caveolin 
plays a crucial role in some non-clathrin pathway as it mediates the formation of 
caveolae at the cell surface and motile caveolin-positive vesicles (Nichols, 2003a). 
The rate of caveolar endocytosis is dependent on the balance between caveolin-1 and 
the raft lipids (cholesterol and glycosphingolipid). For example, overexpression of 
caveolin-1 reduces caveolar internalization rates and accelerates raft-lipid endocytic 
rates (Sharma et al., 2004). Although caveolae-dependent internalization of 
GPI-anchored alkaline phosphatase and Simian virus 40 (SV40) are both dependent 
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on the actin cytoskeleton, low motility of caveolae at the cell surface is dependent on 
cortical actin filaments, and the rapid movement of caveolin-positive vesicles 
(cavicles, cavesomes) in the cytoplasm is dependent on the microtubule network 
(Pelkmans et al., 2002, Mundy et al., 2002). Most caveolin-positive vesicles are 
segregated from the classic endosomal compartments, regulated by non-RTK activity 
and PKCα activity (Pelkmans et al., 2004, Le and Nabi, 2003). However, 
Interleukin-2-receptor-β and some GPI-anchored proteins are targeted to the 
Rab11-positive recycling endosome in some caveolin-independent pathways (Lamaze 
et al., 2001, Sabharanjak et al., 2002). In fact, caveolin-positive vesicles associates 
with early endosome in a Rab5-dependent process (Pelkmans et al., 2004). Therefore, 
the non-classic clathrin-independent endocytic pathways are cross-talked with 
components of the classic endosomal system. 
 
Caveolae (lipid raft) are flask-like invaginations of the plasma membrane, which 
consists of sphingolipids, cholesterol and the caveolin proteins (Razani et al., 2002, 
Rothberg et al., 1992). Caveolae proteins are modified by palmitoylation, which is 
necessary for cholesterol binding and recruitment to plasma membrane. The 
formation of caveolin is dependent on caveolin-1 and cholesterol (Anderson et al., 
1998, Drab et al., 2001, Fra et al., 1995, Kurzchalia et al., 1999).  
 
The non-classic clathrin-independent endocytic pathways are either Dynamin-GTPase 
dependent or Dynamin-GTPase independent. These pathways target cargos to various 
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intracellular compartments such as the Golgi apparatus and the ER, as well as classic 
endocytic compartments such as the recycling endosome (Pelkmans et al., 2001, 
Nichols, 2002, Nichols et al., 2001). The non-classsic clathrin-independent 
endocytosis is an internalization pathway, which is followed not only by TGFβRs, but 
also by other receptors and GPI-anchored proteins (Lamaze et al., 2001).  
 
1.2.3 EGFR and Lipid Raft 
EGFRs are reported to localize in caveolae and monosialotetrahexosylganglioside 
(GM1)-containing lipid raft (Mineo et al., 2002, Roepstorff et al., 2002). Cholesterol 
is essential in the control of EGFR activation. For example, cholesterol depletion 
increases EGF binding, receptors dimerization, autophosphorylation, and tyrosine 
kinase activity. In contrast, cholesterol loading was reported to decrease EGF binding 
and EGFR activation. This is caused by a change in the number of available EGFRs 
for binding, and the mobility of receptors in the plane of the membrane. These data 
imply that EGF signal initiation mediate EGFR exit from both rafts and 
clathrin-dependent endocytosis (Mineo et al., 1999, Anderson 1998).  
 
1.2.4 EGFR Sorting and Clathrin-dependent Endocytosis 
The clathrin adaptors epsin, EPS15 (EGFR-Pathway Substrate-15) and EPS15R 
(EPS15-Related protein) are key components in the EGFR clathrin-dependent 
endocytic pathway. This process is regulated by EGFR-dependent phosphorylation of 
EPS15, and ligand-dependent monoubiquitylation of epsin and EPS15. This 
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monoubiquitylation is mediated by the ubiquitin ligase NEDD4 through the 
ubiquitin-interacting motif (UIM) of epsin and EPS15 (Marmor et al., 2004, Polo et 
al., 2002). The UIM domain is necessary for assembly of multiprotein endocytic 
complexes and form clathrin-coated-pit by association with monoubiquitylated cargo 
and collaborates with other protein-interaction domains such as ENTH (Epsin 
N-Terminal Homology) domain of epsin (Legendre-Guillemin et al., 2004). Cbl is the 
E3 ubiquitinating enzyme responsible for attaching multiple monoubiquitin moieties 
to the cytoplasmic domain of EGFR. This modification is involved in endocytosis and 
the subsequent sorting of internalized EGFR to the MVB (Citri and Yarden, 2006; 
Rubin et al., 2005).  CIN85 and endophilins contains BAR (‘Bin, amphiphysin, Rvs’) 
domain which mediates membrane curvature and facilitate the fission of 
clathrin-coated buds from the membrane. These two proteins are also involved in this 
ubiquitinating process with Cbl (Peter et al., 2004, Soubeyran et al., 2002). 
Furthermore, EGFR also regulates its own endocytosis and mediates the redistribution 
of clathrin at the cell periphery and the monoubiquitylation of the phosphorylation of 
EPS15 and epsin (Wilde et al., 1999, Confalonieri et al., 2000).  
 
After being targeted to early endosomes, the EGFR either recycles back to the cell 
surface, or forms a ternary complex with EPS15, STAM (Signal Transuding Adaptor 
Molecule) and Hrs (Hepatocyte Growth Factor Receptor Tyrosine Kinase Substrate). 
This complex recruits TSG101 (Tumor Susceptibility Gene 101) and the ESCRT 
(Endosomal Sorting Complexes Required for Transport) complexes into the 
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intralumenal vesicles of multivesicular endosomes where its signals are terminated 
(Katzmann et al., 2002).  
 
In the classic clathrin-dependent endocytic pathway, numerous components are 
directly regulated by receptor-dependent phosphorylation and ubiquitination. 
Phospholipids such as PtdIns (4,5) P2 might be generated locally to promote 
clathrin-coated-pit formation. Therefore, protein-protein and protein-lipid interactions 
are crucial for targeting cargo molecules in the clathrin-dependent endocytic pathway 
and intimately connect cell signaling to the endocytic machinery. 
 
More recent data shows that EGFR also moves to the nucleus and acts as an 
organizing center for the induction of signaling pathways (such as MAP pathway) and 
transcription of its target genes, such as cyclin D, iNOS, c-myb and COX-2 (Sorkin et 
al., 2002, Miaczynska et al., 2004, Lo et al., 2006a, Giri et al., 2005). Upon 
stimulation by ligand, EGFR is endocytosed through coated pits and is released into 
the cytoplasm via unknown mechanisms. In the cytoplasm, it binds to importin-b1, 
which transports the EGFR into the nucleus (Figure 1.5) (Linggi and Carpenter, 2006, 















































































































































































































































































































































































































In summary, in the classic clathrin-dependent endocytic pathway, clathrin-mediated 
endocytosis regulates the fate of EGFR and many other receptor systems via 
phosphorylation, multiubiquitylation and the specialized composition of endosomal 
membranes. 
 
1.2.5 EGFR Signaling during Trafficking 
    Previous studies showed that EGFR not only interacts with many of its downstream 
effectors such as SHC (SH2-Domain-Containing Transforming Protein) and Grb2, but 
also recruits SOS (Son-Of-Sevenless) to the endosomes and activates MAPK. The 
internalized activated EGFR promote cell survival through signaling from endosomes 
(Marmor et al., 2004, Di Guglielmo et al., 1994, Haugh et al., 1999, Kranenburg et al., 
1999, Wang et al., 2002).  These data imply that the internalization of EGFR can 
regulate both the nature and magnitude of signaling events and the biological response 
of cell stimulation. In addition, some studies show that H-Ras-dependent activation of 
Raf1 (not K-Ras) is dependent on its cycling between the cell surface and endocytic 
compartments, and is sensitive to the perturbation of lipid rafts. This process of 
H-Ras-dependent activation of Raf1 is due to the repeated and transient access of 
activated EGFR to lipid rafts (Hancock et al., 2003, Parton et al., 2004, Viera et al., 
1996, Roy et al., 2002, Carpenter et al., 2000).  
 
   The dynamics of ErbB-family members internalization are different. The homodimers 
of EGFR are rapidly degraded, and heterodimers of EGFR with either ErbB2 or 
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ErbB3 tend to be recycled. This is due to the stability of the ligand-receptor complex 
in the endocytic pathway and the capacity of the receptor to associate with Cbl 
(Marmor et al., 2004). Furthermore, the study of neuronal differentiation in a 
neuroendocrine cell line indicates that the time of MAPK activation is crucial to 
regulating the biological outcome. This implies that the dynamics of RTK (Receptor 
Tyrosine Kinase) endocytosis has a crucial impact on regulating the biological 
outcome (Vaudry et al., 2002).  
 
   In summary, the sustained endosomal signaling by receptor complexes is essential not 
only for controlling the preferential activation of distinct signaling pathways, but also 
for sustaining multiubiquitylation of EGFR for targeting it to the degradative pathway 
(Mohney et al., 2003, Miaczynska et al., 2004b). Interfering with this process by 
disrupting RTK turnover is a crucial molecular pathology in many cancers. The 
magnitude and kinetics of signaling activation in PTK pathways are essential in 
disease progression. Cbl plays an essential role in this process. The dominant-negative 
mutant of Cbl can block the downregulation of receptors, promote recycling and 
mediate EGF-induced transformation. Herceptin, a humanized version of the L26 
anti-ErbB2 antibody, is used for the treatment of metastatic breast carcinoma because 
it mediates ErbB2 internalization, ubiquitination, and degradation in a Cbl-dependent 
manner (Klapper et al., 2000, Slamon et al., 2001). All these data indicate that there 
are direct regulatory interactions between signaling modules and components of the 
endocytic machinery.  
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1.2.6 Ubiquitination and MVB Generation 
Ubiquitination is a key step of protein degradation in the cell. It mediates the targeting 
of the substrate to the proteosome and lysosome. In general, polyubiquitin chains are 
linked to substates through lysine 48 (K48) (Pickart, et al., 2004, Kirkpatrick et al., 
2006). Recently it is reported that a single ubiquitin molecule binding to its target 
protein is sufficient to direct lysosomal sorting. Diubiquitin chains linked through 
lysine 63 (K63) enhances the efficiency of this process (Hicke, 2001, Marchese and 
Benovic, 2001, Shenoy et al., 2001). Although more than half of the EGFR is 
polyubiquitinated through K63, monoubiquitin at multiple sites directs activated 
EGFR to MVBs (Reggiori et al., 2001, Galan et al., 1997, Haglund et al., 2003, 
Mosesson et al., 2003, Carter et al., 2004, Huang et al., 2006). Cbl is the E3 ubiquitin 
ligase that mediates ubiquitination of EGFR (Thien et al., 2001). Ubiquitination is a 
reversible post-translational modification, and DUBs (deubiquitinating enzymes) are 
proteases for removal of ubiquitin (Nijman et al., 2005, Yao et al., 2002, Verma et al., 
2002). DUBs thus regulate the rate of degradation of ubiquitinated proteins. 
 
ESCRTs (Endosomal Sorting Complexes Required for Transport) are the multimeric 
protein complexes first identified in yeast, which controls the sorting of endosomal 
cargo proteins into internal vesicles of Multivesicular body (MVBs).These complexes 
are highly conserved in both yeast and Mammal. The ESCRT family is made up of 
four distinct protein groups: ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III, which 
are recruited to endosomes through both protein and lipid interactions. For example: 
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ESCRT-0, -II, and –III bind to 3-phosphoinositides through different types of 
lipid-binding domains. In addition, ESCRT-0, -I and –II have UIM domains, which 
are necessary for efficient sorting of ubiquitinylated membrane proteins, while 
ESCRT-III recruts DUBs to remove ubiquitin from cargo and disassemble the 




Hrs (Hepatocyte growth factor Receptor tyrosine kinase Substrate, Vps27p in yeast) 
and STAM (Signal Transuding Adaptor Molecule, Hse1p in yeast) form the 
mammalian ESCRT-0 complex. This complex initiates the engagement of 
ubiquitinated receptor with the MVBs sorting machinery at the endosome through 
UIM (Raiborg et al., 2002, Urbé et al., 2003, Bache et al., 2003a, Mizuno et al., 
2003). ESCRT-0 is associated and recruited to endosome through the FYVE domain 
of Hrs and the PI3P. ESCRT-0 also recruits the ESCRT-I to endosomes through the 
Pro-(Ser/Thr)-X-Pro motif of Hrs (Clague et al., 2003). Both Hrs and STAM directly 
bind to clathrin (Hrs through its Leu-Ile-Ser-Phe motif, while STAM is still unknown).  
Hrs recruits clathrin to endosomes, and this Hrs-clathrin interaction restricts Hrs to the 
microdomains of endosomes and this step is essential for efficient EGF degradation 
(Raiborg et al., 2002, Urbé et al., 2003, Murk et al., 2003, Sachse et al., 2002, 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.7. Domain Organization of Hrs, STAM and TSG101 
The VHS domain is a ~140 residues long domain, whose name is derived from its occurrence in 
VPS-27, Hrs and STAM. The VHS domain is always found at the N- terminus of proteins suggesting 
that such topology is important for function. The domain is considered to have a general membrane 
targeting/cargo recognition role in vesicular trafficking. 
FYVE domain is Zinc-binding domain and present in Fab1, YOTB, Vac1, and EEA1.It targets proteins 
to membrane lipids via interaction with phosphatidylinositol-3-phosphate (PI3P). 
SH3 domain: Src homology 3 domain. 
The ubiquitin-interacting motif (UIM) is found in a number of proteins (Hrs, Epsin, EPS15, S5A and 
STAM) involved in endocytosis and protein trafficking and can bind monoubiquitin as well as 
polyubiquitin chains. 
The UEV (Ubiquitin E2 variant) domain is ubiquitin binding domain of ~145 amino acids found in 
TSG101/Vps23 proteins. It interacts with a ubiquitin molecule and is essential for the trafficking of a 
number of ubiquitylated cargoes to MVBs.    
 
ESCRT-I is a heterotrimeric complex of TSG101 (Vps23p in yeast), VPS28 (Class E 
Vacuolar Protein Sorting 28) and one of four isotype of VPS37 (VPS37 A-D). 
Another subunit Mvb12p is present in Saccharomyces cerevisiae (Oestreich et al., 
2007, Chu et al., 2006, Curtiss et al., 2007, Gill et al., 2007, Bache et al., 2004; 
Bishop and Woodman, 2001, Eastman et al., 2005, Stuchell et al., 2004). ESCRT-I 
interacts with ubiquitin through the N-terminal UEV (ubiquitin E2 variant) domain of 
TSG101 (Bilodeau et al., 2003). ESRCT-I interacts with ESCRT-II via the Vps28p 
binding to Vps36p, and the zinc finger of Vps36p is essential for this interaction. 
Direct interactions of TSG101-VPS22 and TSG101-VPS36 were confirmed by yeast 
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two-hybrid analysis (Gill et al., 2007, Teo et al., 2006, Pineda-Molina et al., 2006, 
Langelier at al., 2006).  
 
Vps22p, Vps25p and Vps36p constitute ESCRT-II, and it binds to ESCTR-III via the 
Vps25p interacting with Vps20p (Langelier et al., 2006, Babst et al., 2002a,b, Teo, et 
al., 2004, Yorikawa et al., 2005). The N-terminal GLUE (GRAM-Like 
Ubiquitin-binding in EAP45) domain of Vps36p binds to PI3P, ubiquitin and the 
Vps28p of ESCRT-I (Teo et al., 2006, Slagsvold et al., 2005, Alam et al., 2004). In 
yeast, ESCRT-II transiently binds to endosomes and faciliates recruitment of 
ESCRT-III complex to membranes. In mammalian cell, some cargo-specific MVB 
pathways might bypass ESCRT-II through ALIX (ALG-2 interacting protein X) or 
other links between ESCRT-I and –III (Babst et al., 2002b, Bowers et al., 2006).  
 
In yeast, ESCRT-III consists of Vps2p, Vps24p, Snf7p and Vps20p, and some 
additional proteins such as Did2p (CHMP1 in mammalian), Vps60p (CHMP5 in 
mammals) and CHM7 (in mammals). These are referred to as ESCRT-III-related 
proteins and all have similar structural organization, with a N-terminal basic and a 
C-terminal acidic region (Babst et al., 2002a, Amerik et al., 2000, Kranz et al., 2001, 
Howard et al., 2001, Nickerson et al., 2006). ESCRT-III interacts with other proteins 
of the MVB pathway, such as ALIX (Bro1p in yeast), the VPS25 subunit of 
ESCRT-II; AMSH or ESCRT-III-related proteins (CHMP1). VPS24 specifically 
associates to PtdIns(3,5)P2. More importantly, multiple ESCRT-III-related proteins 
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interact with the MIT (Microtubule Interacting and Transport) domain of the AAA+ 
ATPase Vps4p (McCullough et al., 2006, Babst et al., 2002a, Teo et al., 2004, von 
Schwedler et al., 2003, Martin-Serrano et al., 2003, Scott et al., 2005). In yeast, the 
class E compartments consist of stacked flat cisternate-like membranes, which are not 
connected to each other. Deletion of any ESCRT-III-related subunit or Class E vps 
mutants causes hydrolases to accumulate with endocytosed receptors in an 
exaggerated perivacuolar class E compartment. This is due to the failure to transport 
newly synthesized hydrolases efficiently to the vacuole (Howard et al., 2001;, 
Yorikawa et al., 2005, Horii et al., 2006, Ward et al., 2005, Skibinski et al., 2005, 
Raymond et al., 1992, Piper et al., 1995, Rieder et al., 1996).  
 
Vps4p disassembles ESCRT complexes through partially unfolding ESCRT subunits, 
thereby disrupting key interactions that maintain the integrity of an ESCRT lattice 
assembly. This disassembly step is essential for sorting of cargo into MVBs (Babst et 
al., 2002a, Nickerson et al., 2006, Azmi et al., 2006, Bache et al., 2006). The 
C-terminal domain of ESCRT-III-related proteins bind to N-terminal MIT domain (a 
three-helix domain) of Vps4p, and recruits it to the endosomal membranes (Scott et al., 
2005). Vta1p (LIP5 in mammalians) facilitates the oligomerization of Vps4p, LIP5 
also interacts with CHMP5 (Vps60p in yeast). Recent studies indicate that Vps60p 




De-ubiquitination of cargo precedes its incorporation into an ILV (Intralumenal 
Vesicle) and serves to maintain levels of free ubiquitin. DUBs might also be recruited 
early in the pathway, where they could provide a proof-reading mechanism and rescue 
cargo before commitment to the degradation pathway. Doa4p is the only DUBs in 
yeast involved in the MVB pathway. It is essential for efficient traffic to the vacuole 
and is recruited to endosomes by Bro1p (Katzmann et al., 2001, Amerik et al., 2004, 
Losko et al., 2001, Reggiori et al., 2001, Dupré and Haguenauer-Tsapis, 2001, Kim et 
al., 2005). UBPY, the Doa4p orthologue in mammalian cells, associates to the SH3 
domain of the ESCRT-0 subunit STAM through two non-canonical binding motifs. 
While AMSH, another DUB, interacts with clathrin and binds multiple CHMPS via 
its N-terminal region. AMSH depletion enhances the kinetics of EGF and EGFR 
degradation (McCullough et al., 2004, Kyuuma et al., 2007, Kato et al., 2000, Kaneko 
et al., 2003), while UBPY depleted cells are unable to degrade RTKs (incliuding 
EGFR) (Ren et al., 2007, Row et al., 2006, Mizuno et al., 2006, Alwan et al., 2007, 
















1.3 TOM1 (Target of the Oncogene v-Myb 1) Family 
TOM1-like1 (TOM1-L1) is a member of the TOM1 protein family of the VHS 
(Vps27/Hrs/STAM) domain proteins. It is characterized by its N-terminal VHS 
domain and a central GAT (GGA and TOM1 homologous) domain followed by a 
C-terminal region. The C-terminal region is not conserved in TOM1 and TOM1-L2 
(Seykora, et al, 2002) (Figure 1.6). TOM1 was originally identified as a target of 
Myb1 as the expression of TOM1 is dramatically increased upon expression of 
oncogenic Myb1 (Burk et al., 1997).   
 
The TOM1 proteins feature high sequence similarity and contain a VHS domain in its 
amino-terminus. The family includes Hrs, STAM1, STAM2, GGA1 (Golgi-localizing, 
γ-adaptin ear domain homology, ADP-ribosylation factor-binding protein 1), GGA2, 
GGA3, TOM1, TOM1-L1 and TOM1-L2. The VHS domain is found in various 
proteins responsible for endocytic processes, signal transduction and in the GGA 
family of proteins (Lohi et al., 2002).  
 
GGA1, GGA2 and GGA3 are homologous proteins associated with the trans-Golgi 
network and other vesicular structures. They serve as effectors of ARF1 
(ADP-ribosylation factor-binding protein) for recruitment onto the trans-Golgi 
network (TGN) (Bonifacino, 2004). The VHS domain of TGN-recruited GGAs is 
known  to  interact  with  an  acidic cluster-dileucine sorting signal present in the  
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Figure1.8 TOM1-L1  
A: Domain Organization of TOM1-L1: TOM1-L1 is characterized by N-terminal VHS domain 
followed by central GAT domain and a C-terminal region in which it interact with Src/Fyn and Grb 2 
(Seykora et al., 2002). 
B: Alignment of TOM1, TOM1-L1 and TOM1-L2. 
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cytoplasmic tail of mannose-6-phosphate receptor (M6PR). This interaction mediates 
sorting of the receptor into the endosomal pathway so that lysosomal enzymes are 
specifically delivered to the lysosomes via the endosomes (Puertollano et al., 2001, 
Nielsen et al., 2001, Zhu et al., 2001, Takatsu et  al., 2001). However, the VHS 
domain of TOM1 and its related proteins do not appear to specify such a function nor 
do the proteins serve as ARF (ADP-ribosylation factor) effectors. The other VHS 
domain proteins such as Hrs and STAM proteins interact with each other and are 
shown to be enriched in the endosomes and thought to function in integrating 
signaling pathway with endocytic traffic (Asao et al., 1997, Bache et al., 2003b).  
 
The GAT domain is found in GGA proteins, TOM1, and TOM1-L1 (Dell'Angelica et 
al., 2000). The GGA-GAT domain interacts with an active form of the ARF and is 
responsible for membrane association of GGA proteins (Hinners and Tooze, 2003, 
Nakayama and Wakatsuki, 2003). In contrast to GGA proteins, the VHS domain of 
TOM1 or TOM1-L1 does not bind to the ACLL motif, and the GAT domain of Tom1 
or TOM1-L1 does not bind to ARF. 
 
TOM1 associates with endofin (Seet et al., 2004), tollip (Yamakami et al., 2003), 
clathrin (Seet et al., 2005) and ubiquitin (Yamakami et al., 2003).  Endofin, clathrin 
and ubiquitin are proteins associated with the endosomal trafficking pathway. TOM1 
is shown to be recruited to the endosome by endofin (an endosomal FYVE domain 
protein) and can subsequently mediate recruitment of clathrin onto the endosome, and 
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is strongly implicated in the regulation of the endocytotic pathway. Until recently, 
TOM1-L1 is known to be phosphorylated by proteins belonging to the Src family of 
protein-tyrosine kinases (Seykora et al., 2002). TOM1-L1 is tyrosine phosphorylated 
by Src and Fyn. The phosphorylation of TOM1-L1 mediates its interaction with the 
signaling molecules Grb2 and PI3K p85 subunit (Seykora et al., 2002). Elevated 
levels of TOM1-L1 promote p44/42 MAPK activity, inhibit keratinocyte proliferation 
and enhance specific aspects of keratinocyte differentiation (Li et al., 2005). 
TOM1-L1 expression is increased in human cutaneous neoplasia and psoriasis (Li et 
al., 2005, Pulitzer M. et al., 2007). The K14-Fyn/TOM1-L1-P transgenic mice, which 
express a nonphosphorylatable TOM1-L1 mutant, show a manifestation of the 
hyperproliferative phenotype. In contrast, K14-Fyn/TOM1-L1 transgenic mice, which 
both Fyn and TOM1L1 expression are increased, did not (Li et al., 2007). 
Phosphorylation of TOM1-L1 and its GAT domain work together to down-regulate 
Fyn (Li et al., 2007). Its role in Src signal transduction is further defined when 
TOM1-L1 was reported to be a negative regulator of Src-receptor activation and 
downstream DNA synthesis in the presence of PDGF (Franco et al., 2006). TOM1-L1 
inhibits SFK interaction with PDGF receptor in caveolae by reducing SFK level in 
caveolae when it associates with CHC (Collin et al., 2007).  
 
The potential involvement of TOM1-L1 in the endocytosis pathway was suggested by 
a recent finding that TOM1-L1 is associated with Hrs and TSG101 /VPS23, which are 
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important for initiating sorting of endocytosed EGFR into multivesicle body (MVBs) 






















1.4 Rational of this Work 
So far a lot of work has already been done on the study of TOM1-L1. Most focused 
on the function of TOM1-L1 in Src/Fyn signaling pathway (Seykora et al., 2002, Li et 
al., 2005, Franco et al., 2006, Collin et al., 2007, Li et al., 2007, Pulitzer M. et al., 
2007). Few papers discuss the interaction of TOM1-L1 and clathrin, ubiquitin, Hrs 
and TSG101 (Puertollano, 2005). It is suggested that TOM1-L1 may be involved in 
both signaling and endocytosis pathways. Thus, there is much interest to investigate 
whether TOM1-L1 is an adaptor protein bridging signaling and endocytosis pathway 
of growth factor receptors, such as EGFR.  
 
In this study, I generated TOM1-L1 specific polyclonal antibodies (anti-TOM1-L1 
and anti-pTOM1-L1), mutants (-SH3, Y460F, Y392F, FDLP450AAAA etc) and 
TOM1-L1 siRNA to investigate the relationship between TOM1-L1 and EGFR, as 
well as the function of TOM1-L1 in EGFR endocytosis and degradation pathways. I 
will provide evidence showing that TOM1-L1 is a regulated adaptor protein bridging 








Chapter 2  Methods and Materials 
 
2.1. cDNA Cloning and Sequencing 
The coding region for human TOM1 and TOM1-L1 was amplified by PCR from 
human fetal brain cDNA library (Clontech) and cloned into pDHAneo, whereas the 
coding region for mouse TOM1-L1 was amplified from American Type Culture 
Collection (ATCC) mouse clones (IMAGE: 6333597, 6393777, 5342991) and cloned 
into pBABEpuro (gift from Dr. Bob Weinberg). All mutants were generated by PCR 
and cloned into pDHAneo, pGEX-4T3 (Amersham) or pBABEpuro. All clones were 
confirmed by DNA sequencing.  
 
2.2. Plasmid Constructs 
pGEX-4T3 was purchased from Amersham (UK); pEGFP-N1 was from BD clontech; 
pBABEpuro Retroviral vector was a gift from Dr. Bob Weinberg. pCIneo was from 
Promega. The N-terminal double HA  tagged pDHAneo, the pCIneo based vector, 
containing a tandem repeat of HA tags upstream of multiple cloning site (MCS), was 
from Dr. Siew Heng Wong (our lab). A plasmid expressing Src (Src cDNA in 
pUSEamp) was from Upstate Biotechnology. 
Table 3:  List of DNA Plasmid Constructs Made for this Study 
Name Insert Vector Purpose in 











1. TOM1-L1-EcoRI-5'  
















1. 1. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
2. TOM1-L1-SalI-Y460F-3' 
5' gcgccgtcgcgg gtcgactc TCA GTC ACC ATC ATT TTG AGC 
















1. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3.TOM1-L1-SalI-SH3-5' 
5' TCA AAC CAG AGT CTG GCA GCT TTG GCC AGC AAT 
CAT CCA GCG 
4.TOM1-L1-SalI-SH3-3' 
5' CGC TGG ATG ATT GCT GGC CAA AGC TGC CAG ACT 












1. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3.TOM1-L1-Grb2-5' 
5' TCA AGC CAC GCA TTT GAT AAT TTT 
4.TOM1-L1-Grb2-3 
5' AAA ATT ATC AAA TGC GTG GCT TGA 
HA-TOM1-
L1 SH3 & 
Y460F 
TOM1-L









1. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
2.TOM1-L1-SalI-420LPPLP-LAALA-5' 
5' TCA AAC CAG AGT CTG GCA GCT TTG GCC AGC AAT 
CAT CCA GCG 
3.TOM1-L1-SalI-420LPPLP-LAALA-3' 
5' CGC TGG ATG ATT GCT GGC CAA AGC TGC CAG ACT 
CTG GTT TGA 
4. TOM1-L1-SalI-Y460F-3' 
5' gcgccgtcgcgg gtcgactc TCA GTC ACC ATC ATT TTG AGC 

















5' AAGGAAAAAA GCGGCCGC TCA TTC ATC TTG TAA 
AAA CAT GTG 
3. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
4. TOM1-L1-SalI-3' 






















5' gcgccgtcgcgg gtcgactc  AGC AAC TTC CTC GAG ATC 
GAT GTG 
2.SNX3-148-NotI-3' 
5' AAGGAAAAAA GCGGCCGC TCA TTC ATC TTG TAA 
AAA CAT GTG 
3. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
4. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
5. TOM1-L1-FDPL450AAAA-5' 
5' GAG GTA ATG GAG GCG GCA GCT GCG GCT CCT GCT 
GTC 
6. TOM1-L1-FDPL450AAAA-3' 














5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-SalI-3' 














5' ggatcccc gaattca CTC CTC GAC CTA AGT CCC AGT CCC 
2. TOM1-L1-SalI-3' 














5' ggatcccc gaattca CTT CAT CCA CAG ATG AAG TTG CTA 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
GST-TOM1- TOM1-L pGEX Expression  1. .TOM1-L1-EcoRI-384-5' 
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5' ggatcccc gaattca AAC CTC ACC TCA AGC CAC GCA TAT 
2. TOM1-L1-SalI-3' 














5' ggatcccc gaattca  AGC AAT CAT CCA GCG ATG ACA 
AAA 
2. TOM1-L1-SalI-3' 













1.  TOM1-L1-EcoRI-286-5' 
5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2.TOM1-L1-446-Sal-3' 













5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-449-Sal-3' 















5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-440-Sal-3' 











1. TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGC AAG AGT CAC CGG GAT 
CCC 
2. TOM1-L1SalI-3’ 




















5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3. TOM1-L1-LPPL424AAAA-5' 
5' TCA AAC CAG AGT GCG GCA GCT GCG CCC AGC AAT 
CAT 
4.TOM1-L1-LPPL424AAAA-3' 

























5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3.TOM1-L1-HPAM431AAAA-5' 
5' TTG CCC AGC AAT GCG GCA GCT GCG ACA AAA AGT 
GAT 
4.TOM1-L1-HPAM431AAAA-3' 





















5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3.TOM1-L1-DLQP438AAAA-5' 
5' ATG ACA AAA AGT GCG GCA GCT GCG CCT AAT TAC 
TAC  
4. TOM1-L1-DLQP438AAAA-3' 























5' ggatcccc gaattca TTT ACT AGA AAC CAA CAA AGG ATT 
2. TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GTC ACC ATC ATT TTG AGC TCC 
TTT 
3. TOM1-L1-FDPL450AAAA-5' 
5' GAG GTA ATG GAG GCG GCA GCT GCG GCT CCT GCT 
GTC 
4. TOM1-L1-FDPL450AAAA-3' 







5' ggatcccc gaattca GAC TTT CTC CTG GGG AAC CCG TTC 
2. TOM1-SalI-3' 
5' gcgccgtcgcgg gtcgactc AAG GCA AAC AGC ATG TCA TCA 
TCT 








1. m-TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGG AAG AGT CAC CGC GAT  
2. m-TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GCA GTC ACT ATG ACT TTG AGC 











1. m-TOM1-L1-EcoRI-5'  





5' gcgccgtcgcgg gtcgactc GCA GTC ACT ATG ACT TTG AGC 
TTC TTT CTG  
3. m-TOM1-L1-Y392F-5' 
TCG AGT CAC ACA GCT GAT AAT TTT CAC 
4. m-TOM1-L1-Y392F-3' 













1. m-TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGG AAG AGT CAC CGC GAT  
2.m-TOM1-L1-Y457F-SalI-3' 
5' gcgccgtcgcgg gtcgactc GCA GTC ACT ATG ACT TTG AGC 
















1. m-TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGG AAG AGT CAC CGC GAT  
2. m-TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GCA GTC ACT ATG ACT TTG AGC 
TTC TTT CTG 
3. m-TOM1-L1-DLQP437AAAA-5’ 
5' CTA AAA GAC GGC GCG GCA GCT GCG CCC AAT TAC 
TAC  
4. m-TOM1-L1-DLQP437AAAA-3’ 



















1. m-TOM1-L1-EcoRI-5'  
5'ggatcccc gaattca GCG TTT GGG AAG AGT CAC CGC GAT  
2. m-TOM1-L1-SalI-3' 
5' gcgccgtcgcgg gtcgactc GCA GTC ACT ATG ACT TTG AGC 
TTC TTT CTG 
3. m-TOM1-L1-FDPL449AAAA-5' 
5' GAG GTA ATG GAG GCG GCT GCT GCG GCT CCC ACT 
ACA 
4. M-TOM1-L1-FDPL449AAAA-3' 
5' TGT AGT GGG AGC CGC AGC AGC CGC CTC CAT TCA 
CTC 
 
2.2.1 HA-TOM1-L1, HA-TOM1-L1 Y460F and GFP-TOM1-L1 
HA-TOM1-L1: The entire coding sequence of TOM1-L1 cDNA was PCR-amplified 
from Human fetal Brain cDNA library (Clontech) with primers: TOM1-L1-EcoRI-5' 
and TOM1-L1-SalI-3', and the resulting PCR fragments were digested by EcoRI/SalI 
and ligated into the corresponding sites of pDHAneo.  
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HA-TOM1-L1 Y460F: The entire coding sequence of TOM1-L1 Y460F cDNA was 
PCR-amplified from Human fetal Brain cDNA library (Clontech) with primers: 
TOM1-L1-EcoRI-5' and TOM1-L1-SalI-Y460F-3', and the resulting PCR fragments 
were digested by EcoRI/SalI and ligated into the corresponding sites of pDHAneo. 
GFP-TOM1-L1: The entire coding sequence of TOM1-L1 cDNA was 
PCR-amplified from Human fetal Brain cDNA library (Clontech) with primers: 
TOM1-L1-EcoRI-5' and TOM1-L1-SalI-3', and the resulting PCR fragments were 
digested by EcoRI/SalI and ligated into the corresponding sites of pEGFR-N1 
(Clontech). 
 
2.2.2 HA-TOM1-L1 SH3, HA-TOM1-L1 Y392F and HA-TOM1-L1 Y460F & 
SH3 
HA-TOM1-L1 SH3: The entire coding sequence of TOM1-L1 SH3 mutant was 
generated by the overlapping PCR mutagenesis strategy from HA-TOM1-L1 
construct with two primers pairs: TOM1-L1-EcoRI-5'/ TOM1-L1-SalI-SH3-3' and 
TOM1-L1-SalI-3'/TOM1-L1-SalI-SH3-5'. Both PCR products were gel-purified and 
added to second round of PCR in equal amounts. The full-length fragment with the 
SH3 mutation was synthesized with primers: TOM1-L1-EcoRI-5' and 
TOM1-L1-SalI-3'.The resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of pDHAneo.  
HA-TOM1-L1 Y392F: The entire coding sequence of TOM1-L1 Y392F mutant was 
generated by the overlapping PCR mutagenesis strategy from HA-TOM1-L1 
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construct with two primers pairs: TOM1-L1-EcoRI-/TOM1-L1-Grb2-3' and 
TOM1-L1-SalI-3'/TOM1-L1-Grb2-5'. Both PCR products were gel-purified and 
added to second round of PCR in equal amounts. The full-length fragment with the 
Y392F mutation was synthesized with primers: TOM1-L1-EcoRI-5' and 
TOM1-L1-SalI-3'. The resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of pDHAneo.  
HA-TOM1-L1 Y460F & SH3: The entire coding sequence of TOM1-L1 SH3 mutant 
was generated by the overlapping PCR mutagenesis strategy from HA-TOM1-L1 
Y460F mutant construct with two primers pairs: TOM1-L1-EcoRI-5'/ 
TOM1-L1-SalI-SH3-3' and TOM1-L1-SalI-Y460F-3'/TOM1-L1-SalI-SH3-5'. Both 
PCR products were gel-purified and added to second round of PCR in equal amounts. 
The full-length fragment with the Y460 & SH3 mutation was synthesized with 
primers: TOM1-L1-EcoRI-5' and TOM1-L1-SalI-Y460F-3'. The resulting PCR 
fragments were digested by EcoRI/SalI and ligated into the corresponding sites of 
pDHAneo. 
 
2.2.3 HA-TOM1-L1-PX and HA-TOM1-L1-PX FDPL450AAAA 
PX pDHAneo: The coding sequence of PX domain of SNX3(25-148aa) cDNA was 
PCR-amplified from SNX3 construct (Xu et al., 2001)(provided by Lu Lei of our lab) 
with primers: SNX3-25-SalI-5' and SNX3-148-NotI-3', and the resulting PCR 
fragments were digested by SalI/NotI and ligated into the corresponding sites of 
pDHAneo.   
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HA-TOM1-L1-PX: The entire coding sequence of TOM1-L1 cDNA was 
PCR-amplified from HA-TOM1-L1 construct with primers: TOM1-L1-EcoRI-5' and 
TOM1-L1-SalI-3', and the resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of PX pDHAneo 
HA-TOM1-L1-PX FDPL450AAAA: The entire coding sequence of TOM1-L1 
FDPL450AAAA mutant was generated by the overlapping PCR mutagenesis strategy 
from HA-TOM1-L1 construct with two primers pairs: TOM1-L1-EcoRI-5'/ 
TOM1-L1-FDPL450AAAA-3' and TOM1-L1-FDPL450AAAA-5'/ TOM1-L1-SalI-3'. 
Both PCR products were gel-purified and added to second round of PCR in equal 
amounts. The full-length fragment with the FDPL450AAAA mutation was 
synthesized with primers: TOM1-L1-EcoRI-5' and TOM1-L1-SalI-3'.The resulting 
PCR fragments were digested by EcoRI/SalI and ligated into the corresponding sites 
of PX pDHAneo. 
 
2.2.4 GST-TOM1-L1 286-476 and GST-TOM1-L1 Deletion Constructs (316-476, 
360-476,384-476,420-476,286-446,286-449,286-440) 
The coding sequence of TOM1-L1 286-476 and the indicated amino acids were 
PCR-amplified from HA-TOM1-L1 construct. The resulting PCR fragments were 




2.2.5 GST-TOM1-L1 286-476 LPPL424AAAA, GST-TOM1-L1 286-476 
HPAM431AAAA, GST-TOM1-L1 286-476 DLQP438AAAA and GST-TOM1-L1 
286-476 FDPL450AAAA 
GST-TOM1-L1 286-476 LPPL424AAAA: The coding sequence of TOM1-L1 
286-476 LPPL424AAAA mutant was generated by the overlapping PCR mutagenesis 
strategy from HA-TOM1-L1 construct with two primers pairs: 
TOM1-L1-EcoRI-286-5'/TOM1-L1-LPPL424AAAA-3' and TOM1-L1-LPPL424 
AAAA-5'/TOM1-L1-SalI-3'. Both PCR products were gel-purified and added to 
second round of PCR in equal amounts. The C-terminal fragment with the 
LPPL424AAAA mutation was synthesized with primers: TOM1-L1-EcoRI-286-5' 
and TOM1-L1-SalI-3'.The resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of pGEX-4T3 (Amersham Pharmacia). 
GST-TOM1-L1 286-476 HPAM431AAAA: The coding sequence of TOM1-L1 
286-476 HPAM431AAAA mutant was generated by the overlapping PCR 
mutagenesis strategy from HA-TOM1-L1 construct with two primers pairs: 
TOM1-L1-EcoRI-286-5'/TOM1-L1-HPAM431AAAA-3' and TOM1-L1-HPAM431 
AAAA-5'/TOM1-L1-SalI-3'. Both PCR products were gel-purified and added to 
second round of PCR in equal amounts. The C-terminal fragment with the 
HPAM431AAAA mutation was synthesized with primers: TOM1-L1-EcoRI-286-5' 
and TOM1-L1-SalI-3'.The resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of pGEX-4T3 (Amersham Pharmacia). 
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GST-TOM1-L1 286-476 DLQP438AAAA: The coding sequence of TOM1-L1 
286-476 DLQP438AAAA mutant was generated by the overlapping PCR 
mutagenesis strategy from HA-TOM1-L1 construct with two primers pairs: 
TOM1-L1-EcoRI-286-5'/TOM1-L1-DLQP438AAAA-3' and TOM1-L1-DLQP438 
AAAA-5'/TOM1-L1-SalI-3'. Both PCR products were gel-purified and added to 
second round of PCR in equal amounts. The C-terminal fragment with the 
DLQP438AAAA mutation was synthesized with primers: TOM1-L1-EcoRI-286-5' 
and TOM1-L1-SalI-3'.The resulting PCR fragments were digested by EcoRI/SalI 
and ligated into the corresponding sites of pGEX-4T3 (Amersham Pharmacia). 
GST-TOM1-L1 286-476 FDPL450AAAA: The coding sequence of TOM1-L1 
286-476 FDPL450AAAA mutant was generated by the overlapping PCR mutagenesis 
strategy from HA-TOM1-L1 construct with two primers pairs: 
TOM1-L1-EcoRI-286-5'/TOM1-L1-FDPL450AAAA-3' and TOM1-L1-FDPL450 
AAAA-5'/TOM1-L1-SalI-3'. Both PCR products were gel-purified and added to 
second round of PCR in equal amounts. The C-terminal fragment with the 
FDPL450AAAA mutation was synthesized with primers: TOM1-L1-EcoRI-286-5' 
and TOM1-L1-SalI-3'. The resulting PCR fragments were digested by EcoRI/SalI and 





2.2.6 TOM1, m-TOM1-L1, m-TOM1-L1 Y392F, m-TOM1-L1 Y457F, 
m-TOM1-L1 DLQP437AAAA and m-TOM1-L1 FDLP449AAAA 
TOM1: The entire coding sequence of TOM1 cDNA was PCR-amplified from PCR 
from human fetal brain cDNA library (Clontech) with primers: TOM1-EcoRI-5' and 
TOM1-SalI-3', and the resulting PCR fragments were digested by EcoRI/SalI and 
ligated into the corresponding sites of pBABEpuro. 
m-TOM1-L1: Mouse TOM1-L1 was amplified from American Type Culture 
Collection (ATCC) mouse clones (IMAGE:6333597, 6393777, 5342991) with 
primers: m-TOM1-L1-EcoRI-5' and m-TOM1-L1-SalI-3', and the resulting PCR 
fragments were digested by EcoRI/SalI and ligated into the corresponding sites of 
pBABEpuro.  
m-TOM1-L1 Y392F: The entire coding sequence of  mouse TOM1-L1 Y392F 
mutant was generated by the overlapping PCR mutagenesis strategy from 
m-TOM1-L1 construct with two primers pairs:m-TOM1-L1-EcoRI-5'/m-TOM1-L1- 
Y392F-3' and m-TOM1-L1-SalI-3'/m-TOM1-L1-Y392F-5'. Both PCR products were 
gel-purified and added to second round of PCR in equal amounts. The full-length 
fragment with the Y392F mutation was synthesized with primers: 
m-TOM1-L1-EcoRI-5' and m-TOM1-L1-SalI-3'. The resulting PCR fragments were 
digested by EcoRI/SalI and ligated into the corresponding sites of pBABEpuro.  
m-TOM1-L1 Y457F: The entire coding sequence of  mouse TOM1-L1 Y457F  
mutant was generated by the overlapping PCR mutagenesis strategy from 
m-TOM1-L1 construct with two primers pairs:m-TOM1-L1-EcoRI-5'/ m-TOM1-L1- 
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Y457F-3' and m-TOM1-L1-SalI-3'/ m-TOM1-L1-Y457F-5'. Both PCR products were 
gel-purified and added to second round of PCR in equal amounts. The full-length 
fragment with the Y457F mutation was synthesized with primers: 
m-TOM1-L1-EcoRI-5' and m-TOM1-L1-SalI-3'. The resulting PCR fragments were 
digested by EcoRI/SalI and ligated into the corresponding sites of pBABEpuro.  
m-TOM1-L1 DLQP437AAAA: The entire coding sequence of  mouse TOM1-L1 
DLQP437AAAA mutant was generated by the overlapping PCR mutagenesis strategy 
from m-TOM1-L1 construct with two primers pairs: m-TOM1-L1-EcoRI-5'/ 
m-TOM1-L1-DLQP437AAAA-3' and m-TOM1-L1-SalI-3'/m-TOM1-L1-DLQP437 
AAAA-5'. Both PCR products were gel-purified and added to second round of PCR in 
equal amounts. The full-length fragment with the DLQP437AAAA mutation was 
synthesized with primers: m-TOM1-L1-EcoRI-5' and m-TOM1-L1-SalI-3'. The 
resulting PCR fragments were digested by EcoRI/SalI and ligated into the 
corresponding sites of pBABEpuro.  
m-TOM1-L1 FDLP449AAAA: The entire coding sequence of  mouse TOM1-L1 
FDLP449AAAA mutant was generated by the overlapping PCR mutagenesis strategy 
from m-TOM1-L1 construct with two primers pairs:m-TOM1-L1-EcoRI-5'/ 
m-TOM1-L1-FDLP449AAAA-3' and m-TOM1-L1-SalI-3'/m-TOM1-L1-FDLP449 
AAAA-5'. Both PCR products were gel-purified and added to second round of PCR in 
equal amounts. The full-length fragment with the FDLP449AAAA mutation was 
synthesized with primers: m-TOM1-L1-EcoRI-5' and m-TOM1-L1-SalI-3'. The 
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resulting PCR fragments were digested by EcoRI/SalI and ligated into the 
corresponding sites of pBABEpuro. 
 
2.3. Purification of GST-fusion Proteins 
GST-fusion proteins were purified according to Amersham Pharmacia’s protocol.  
Bacterial cultures were grown to an A600 of 0.6-0.8 at 37 ºC and overnight induction 
with 1 mM IPTG at room temperature. The cells were centrifuged at 4000g 15 
minutes at 4ºC, and pellets were resuspended in phosphate-buffered saline (PBS) 
buffer, and lysis by sonication at 4ºC. Cell lysates were clarified by centrifugation and 
the supernatant was incubated with column glutathione Sepharose 4B (Amersham 
Pharmacia) for 4 hours at 4 ºC, and were washed 5 times with cold-PBS. GST-fusion 
protein was eluted with 10 mM reduced glutathione in GST purification buffer (50 
mM Tris-Cl, pH 8.5 and 150 mM NaCl) or digested by incubated with thrombin 
(diluted in GST purification buffer) 6 hours in room temperature, and were stored at 
-20 ºC. 
 
2.4. Immunization of Rabbits and Affinity Purification of Antibodies 
Anti-TOM1-L1 polyclonal antibodies were raised by injecting purified 
GST-TOM1-L1 (285-476) fusion protein into rabbits while 
anti-Phospho-Tyrosine-TOM1-L1 polyclonal antibody was raised by Genemed 
Synthesis Inc by injecting the peptide 455TEAIY(phospho)EEIDAHQHKGC471.  In 
brief, GST-TOM1-L1 and the peptide TEAIY(phospho)EEIDAHQHKG with a 
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C-terminal Cys residue for conjugation to carrier protein were synthesized and 
injected to rabbit with freud’s complete adjuvant. Booster injections with the antigens 
in Freund’s incomplete adjuvant were administered every 20 days, and 50 ml 
antiserums bleed after every of the 4th injections. A total 200ml blood was collected 
from each rabbit. Anti-TOM1-L1 serum was purified using an affinity matrix 
prepared by chemically coupling the antigen to glutathione-Sepharose using dimethyl 
pimelimidate dihydrochloride (Sigma). Antibody bound to the Sepharose was eluted 
with ImmunoPure IgG elution buffer (Pierce) and neutralized in 1 M Tris-HCl, pH 8. 
The antibody was then dialyzed against PBS (pH 7), and concentrated using Centricon 
(Millipore) at 5000g. Phospho-peptide antibody was purified by 2-steps peptide 
affinity purification: anti-pTOM1-L1 serum was purified by non-phospho-peptide 
column, followed by incubating with phospho-peptide column and the elution 
solution ImmunoPure IgG elution buffer (Pierce) which was collected. Specific 
blocking of the antibody with its antigen was achieved by incubating the antibody 
with a 50-fold excess of GST-TOM1-L1 (285-476) fusion protein for at least 4 hours 
at 4ºC. Nonspecific blocking was similarly carried out with GST-TOM1 (300-492) 
fusion protein (Seet et al., 2004).  
 
2.5. Antibodies 
The monoclonal antibody against EGFR, pEGFR, and EEA1 were from BD 
Transduction Laboratories while the monoclonal antibody against LAMP1 was from 
Developmental studies Hybridoma Bank. The anti- phosphotyrosine (4G10) 
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monoclonal antibody, polyclonal anti-HA, anti-Myc, anti-Rho GDI and monoclonal 
anti-Ras and anti-Src were from Upstate Biotechnology. Polycloncal anti-clathrin, 
anti-TfR, anti-Cbl, anti-Grb2 and anti-AP2 α antibody were obtained from Santa Cruz. 
The monoclonal anti-clathrin antibody was from Research Diagnostics Inc. Polyclonal 
anti- human Syntaxin 5 was derived by injecting 6XHis-tagged Syntaxin 5 
(Dr.Subramaniam, our lab).  Polyclonal anti- human anti-Sec23 was from Miss Ong 
Yan Shan (Abcam). Polyclonal anti-GAPDH was from Abcam. The secondary 
fluorescein isothiocyanate (FITC-), Texas Red-, or Cy3-conjugated anti-mouse or 
anti-rabbit antibodies were from Jackson ImmunoReaserch.  
 
2.6. Cell Culture  
A431, Cos7, NIH3T3, SFY were purchased from the American Type Culture 
Collection (ATCC). Phoenix-Ampho and Phoenix-Eco cells were gifts from Nolan 
Lab, Stanford. Hrs knockout, Hrs rescue and STAM 1/2 knockout cell were gifts from 
Dr. Sugamura Lab, Japan. All these cells were grown in Dulbecco modified Eagle 
medium supplemented with 10% fetal bovine serum and in a 5% CO2 incubator at 37 
ºC as described previously (Seet et al., 2004). 
 
2.7.  Transient and Stable Expression  
Transient transfection was done in 6-wells plates for the indirect immunofluorescence 
microscopy, or in 10-cm plates for immunoprecipitation and western blotting. The 
cells were transfected with Lipofectamine 2000 (Gibco) according to manufacturer’s 
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protocol: for 6-well plates, 4µg DNA and 10 ul lipofectamine 2000 were diluted in 
0.8ml Opti-MEM respectively, and incubated for 5 minutes at room temperature 
separately. The two solutions were gently mixed and incubated for 25 minutes at 
room temperature. The DNA- Lipofectamine complexes were added to 6-wells plates 
with 2 ml fresh medium. The cells were tested for transgene expression after 24 hours. 
Stable pooled cells were selected by culture in Geneticin (Invitrogen) for at least 2 
weeks. For 10-cm plates, lipofectamine 2000, DNA and Opti-MEM were increased in 
proportion to the relative surface area. The cells were then lysed for subsequent GST 
pull-down assays, immunoprecipitation experiments, or immunofluorescence analysis 
24-48h post-transfection (Seet et al., 2004). 
 
2.8. Retroviral Infection 
For retroviral infection, packing cell Phoenix-Ampho (for human cells) or 
Phoenix-Eco (for mouse cells) was transfected by Lipofectamine 2000 (Invitrogen) 
according to the manufacturers’ instruction as described previously. The supernatant 
was recovered and used to infect the A431 cells (protocols from Nolan lab). On day 1, 
and Phoenix-Ampho or Phoenix-Eco cells were plated to 10-cm plate and grown to 
70% confluency. The Phoenix cells were then transfected by lifectamine 2000 
according to manufacturers’ protocol as described previously 24 hours later. Media 
was changed to fresh complete DMEM (10ml) and the cells were left at 32ºC on day 3, 
at the same time, the target cells were split and plated into 6-well plate. On day 4, the 
supernatant was harvested from the packing cells and centrifuged for 5 min at 1000g, 
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then filtered through 0.45 μm filter, and viral supernatant were concentration to >108 
cfu/ml by superspeed centrifugated at 20000g for 4 hours, the viral pellet was 
resuspended in fresh medium by gentle pipetting. After the media was moved from 
the target cells and 2 ml of the filtered supernatant was added to the target cells with 5 
µg/ml polybrene, the cells were placed at 32ºC with gentle shaking, and the remaining 
virus supernatant kept at 4ºC. On day 5, the virus supernatant was removed from the 
target cells, changed to fresh complete DMEM and placed at 37ºC for at least 8 hours. 
Virus infection was repeated 2 more times and selected with puromycin (0.5-2 µg/ml) 
for 1 week and assessed for the expression level of the protein of interest. 
 
2.9. siRNA Knockdown 
siRNA pools of negative control (Non-targetings siRNA), GAPD, TOM1-L1, AP2 α, 
Cbl, and Grb2 were synthesized by Dharmacon Research (Lafayette, CO), whereas 
UAAUCCAAUUCGAAGACCAAU  (Motley et al., 2003) and CGA CAA GAA 
CCC ACA CGU CdTdT (Dharmacon Research) were synthesized for knocking down 
clathrin heavy chain and Hrs, respectively. All oligos were designed based on human 
sequences. Dharmacon knockdown control pool (Non-targetings siRNA) and GAPD 
knock down pool were used as knock down negative controls. A431 cells in 6-wells 
plates (30% confluency; 2.5 ml of normal culture medium without antibiotics per well) 
were transfected with 1µl of 100 pmol siRNA duplex and 5 µl of lipofectamine2000 
reagent (Invitrogen) according to the manufactures’ instructions. For biochemical 
experiments, cells were transfected with anti-TOM1-L1 siRNA pool twice, with an 
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interval of 24 hours, and replated 4-6 hours after the second transfection. Cells were 
routinely analyzed by western blotting 72 hours post transfection. Biochemical 
experiments were included only when the level of knockdown exceeded an estimated 
70%. For immunofluorescence studies, cells were transfected with anti-TOM1-L1 
siRNA, and replated with fresh medium 4-6 hours post transfection. For double knock 
down experiments, the total siRNA oligos were kept the same amount by addition two 
siRNA oligos. 
Dharmcon siRNA Pool for TOM1-L1: 
1. Sense Sequence:                    UAA UCA ACU UUC AGG CUU AUU 
Antisense Sequence:              (P) UAA GCC UGA AAG UUG AUU AUU 
2. Sense Sequence:                    GGA UGU AAG CGA AGU CAA AUU 
Antisense Sequence:              (P) UUU GAC UUC GCU UAC AUC CUU 
3. Sense Sequence:                    GGA UAU GAG AGG UUU ACU AUU 
  Antisense Sequence:              (P) UAG UAA ACC UCU CAU AUC CUU 
4. Sense Sequence:                    CAA GAU CUC CUC GAC CUA AUU 
  Antisense Sequence:              (P) UUA GGU CGA GGA GAU CUU GUU 
 
2.10. EGF, PDGF-bb, or FGF2 Stimulation 
A431, NIH 3T3 or SYF cells were serum starved in DMEM with 0.1% FBS for 16 
hours, and washed one time by starvation medium, then incubated with EGF, 
PDGF-bb, or FGF2 at a final concentration of 100, 50 , 20 ng/ml, respectively at 37ºC 
for different times. In some EGF experiments, cells were treated with 10 nM PP1 
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(Calbiochem) for 45 minutes and washed 3 times with PBS before treatment with 100 
ng/ml EGF. After stimulation, the cells were washed one time by cold PBS, then were 
lysed in lysis buffer containing 29 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% 
Triton X-100, Complete EDTA-free protease inhibitor mixture (Roche Diagnostics 
GmbH), 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 50 mM NaF. 
The cell lysates were centrifuged at 11,000g 30 minutes at 4ºC, and the supernatant 
was collected for western blotting; or cells were fixed by paraformaldehyde (PFA) for 
indirect immunofluorescence microscopy.  
 
2.11. EGF Internalisation 
A431 cells were starved overnight in DMEM containing 50 mM HEPEs and 1% BSA 
before being incubated with 20 ng/ml of Texas Red-EGF for 1 hour at 4 ºC. The cells 
were then washed 3 times with DMEM containing 50 mM HEPEs and 1% BSA.  
After internalization for 0 or 3 hours in DMEM containing 10% serum at 37 ºC, the 
cells were washed 3 times with ice-cold PBS and then analyzed.  Western blots 
results of EGFR degradation were quantified by densitometry using Quantity One 
software (Bio-Rad, Hercules, CA). 
 
2.12. Immunoprecipitation and Western Blotting 
Cells were lysed in lysis buffer containing 20 mM Tris-HCl (pH7.4), 150 mM NaCl, 
0.5% Triton X-100, Complete EDTA-free protease inhibitor mixture (Roche 
Diagnostics GmbH), 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 50 
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mM NaF. The cell lysates were centrifuged at 11,000g 30 minutes at 4ºC, and the 
supernatant was collected for immunoprecipitation experiments or western blotting. 
For immunoprecipitation, the supernatant was incubated with 40 µl 50% protein 
A-Sepharose CL-4B (Amersham Biosciences) and 5 µg antibody for 12 hours at 4ºC. 
The beads were washed 3 times with ice-cold lysis buffer and were heated with 
sample loading buffer 5 minutes at 95ºC, and run out on SDS-polyacrylamide gels 
and transformed onto nitrocellulose membranes. These membranes were blocked by 
3% milk in Tris-buffered saline/Tween 20 (TBST) buffer (20mM Tris-HCl pH7.4, 
150mM Nacl, and 1% Tween-20) 3 hours at room temperature, then incubate with 
primary antibody in 3% milk/TBST 1 hour at room temperature, following 3 times 
washing with TBST (10 minutes each time). The membranes were then incubated 
with horseradish peroxidase-conjugated secondary antibody (Jackson 
ImmunoResearch) in 3% milk/TBST, and washed 3 times with TBST (10 minutes 
each time). Specific protein bands were visualized by the SuperSignal West Pico 
Chemiluminescence Substrate (Pierce). Protein loading was assessed by detection for 
β-tubulin. 
 
2.13. Indirect Immunoflurescence Microscopy 
Immunofluorescence microscopy was performed as described previously (Seet and 
Hong, 2001). Cells grown on coverslips were washed 3 times with PBSCM (PBS+ 
1mM CaCl2 + 1mM MgCl2), then fixed by 3.7% paraformaldehyde (PFA) in PBS 20 
minutes at room temperature. After fixing, cells were washed 3 times with PBSCM, 
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and blocked with 50mM NH4Cl2 in PBSCM 5 minutes at room temperature, then 
repeat one more time block and washed 3 times with PBSCM, followed by 
permeabilization with 0.1% Sapinon in PBSCM 5 minutes at room temperature, and 
washed 5times with PBSCM. The cells were incubated with primary antibody in 
fluorescence dilution buffer (PBSCM with 5% normal goat serum, 5% fetal bovine 
serum and 2% bovine serum albumin, pH7.6) 1 hour at room temperature, followed 
by washing 10 times with PBSCM, and incubated with secondary antibodies for 1 
hour at room temperature, then washed 10 times with PBSCM and mounted with 
Vectashield (Vector Laboratiories) and sealed by nail varnish. Cells were viewed and 
the images taken using a confocal laser scanning microscope (MRC1024, Zeiss) as 
described previously (Seet et al., 2004). 
 
2.14. Cytosol Extract 
Cells grown on 10-cm dishes were washed first with ice-cold PBS and then with 
cytosol buffer (0.2 M sucrose, 25 mM HEPEs pH7.0, 125 mM KOAc, 2.5 mM 
MgOAc, 1 mM DTT) in the present of protease inhibitor cocktail (Roche Diagnostics 
GmbH). The cell monolayer was then scraped and homogenized by passing through a 
27-gauge needle 10 times. The subsequent cell suspension was then centrifuged at 
500g for 5 minutes to obtain the post-nuclear supernatant (PNS). The cytosol extract 
was obtained by high-speed centrifugation at 300,000g for 1 hour in a Beckman 
SW600 rotor. The protein concentration of the cytosol extract was measured by the 
Coomassie Plus Reagent (Pierce) (Seet et al., 2005). 
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2.15. Gel Fractionating 
A431 cells were lysed in PBS containing protease inhibitor cocktail (Roche), and 
broken at -20ºC. The cell lysate was centrifuged at 2000g for 5 minutes to remove the 
nuclei, and the postnuclear supernatant was then centrifuged at 350,000g for 30 
minutes using a TLA-100 rotor. The supernatant was kept as cytosol fraction and was 
injected in Superose 6 column of AKTApurifier system (GE). It was fractionated 
according to manufacturers’ protocol with the flow rate was 0.2ml/min. 0.6ml fraction 
was collected each time. A total 59 samples were collected and 12 pools were 
constituted by mixing each 100ml of every 5 samples. All samples (each fraction and 
pool) were incubated with trichloroacetic acid (TCA) (10% final concentration) at 4ºC 
for 1 hour, then TCA-precipiatiable proteins were pelleted by centrifugation at 
11,000g at 4ºC for 10 minutes, washed 2 times with ice-cold acetone and dried in air. 
The pellets were subsequently resuspended in 10mM NaOH, and boiled in 95ºC for 5 
minutes with SDS-sample buffer. Samples were analysed by SDS-PAGE and western 
blotting to detect endogenous TOM1-L1 and Sec-23 (as control) with anti-TOM1-L1 
or anti-Sec 23 antibodies respectively.  
 
2.16. Clathrin-Binding Assay 
Clathrin-binding assay was performed as described previously (Mullins and 
Bonifacino, 2001).  Briefly, the soluble cytosolic protein extract (2.5 mg/ml. 1ml) 
was centrifuged 11,000g 10 minutes at 4ºC to remove aggregates, then incubated with 
100 μg GST or GST fusion (50 ul bed volume) protein for 4 hours at 4ºC by rotation. 
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The pellet was centrifuged at 1000g for 1 minute at 4ºC, and washed with ice-cold 
cytosol buffer. This process was repeated a total of 3 time. After washing, the pellets 
were resuspended in 50 μl of 4X sample loading buffer, and heated at 95ºC for 5 
minutes, then aliquots representing 20ug was run on SDS-PAGE and analyzed by 
western blotting. 
 
2.17. Cell Surface Biotinylation and Stripping 
Cells grown on 10-cm dishes to 90-95% confluency were washed with ice-cold 
PBSCM (PBS with 1 mM CaCl2 and 1 mM MgCl2) and then incubated with 10 ml of 
1.5 mg/ml fresh sulfo-NHS-SS-biotin for 30 minutes at 4ºC. The unreacted biotin was 
quenched twice with cold 50 mM glycine in PBSCM at 4ºC. Cells were then supplied 
with fresh DMEM containing 100 ng/ml EGF, and were incubated either at 4ºC to 
block membrane trafficking (negative control) or at 37ºC for various times to allow 
endocytosis to occur. After endocytosis, cells were subjected to 2 X 15 minutes 
incubation with glutathione cleavage buffer (50 mM glutathione in 75 mM NaCl, 10 
mM EDTA containing 1% BSA, 0.075 M NaOH) at 4ºC in attempt to clear off the 
biotin attached to the surface exposed proteins.  Unreacted glutathione was quenched 
twice (5 minutes each) at 4ºC with 5 mg/ml of iodoacetamide in PBSCM.  Cell 
lysates were incubated with Immobilized Neutr Avidin Gel (Pierce) for 1 hour at 
room temperature. The proteins retained by the beads were resolved by SDS-PAGE 
and analyzed by immunoblot.  All immunoblot results were quantified by 
densitometry using the Quantity One software (Bio-Rad, Hercules, CA). 
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2.18. Biochemical Subcellular Fractionation 
A431 cells were broken with a ball-homogenizer in homogenization buffer (20mM 
HEPEs pH7.3, 100mM NaCl, 5 mM MgCl2) in the presence of EDTA-free proteinase 
inhibitor cocktail (Roche). The cell lysate was centrifuged at 2000g for 5 minutes to 
remove the nuclei, and the postnuclear supernatant was then centrifuged at 85,000 
rpm for 30 minutes using a TLA-100 rotor. This supernatant was kept as cytosol 
fraction, while the pellet was dissolved in homogenization buffer containing 1% 
Triton-100 for 1 hour on ice. The extracted proteins were kept as membrane fraction 
upon removed of insoluble materials by  centrifuged at 11,000g for 30 minutes. The 
proteins concentrations of both fractions were quantified, and ~15 μg of cytosolic and 
membrane proteins was analyzed by SDS-PAGE and processed for western blotting 
to detect TOM1-L1, Rho GDI (as a cytosolic marker) and Syntaxin 5 (as a membrane 
marker) (From Dr.Wang Tuanlao, our lab). 
 
2.19. Ras Activation Assay 
Ras activation assay was performed according to manufacturers’ protocol (Upstate 
Biotechnology). Basically, since only activated Ras (Ras-GTP) can associate with the 
RBD domain of Raf-1, GST-Raf1-RBD coupled to glutathione agarose will pull down 
active GTP-bound Ras from cell lysates and the fraction of activated Ras is 
determined by immunoblotting with anti-Ras antibody.  In brief, cells were cultured 
to ~85-90% confluency, and stimulated by EGF to activate Ras. The cells were lysed 
with Mg2+ lysis/wash (MLB) buffer (25mM HEPES pH7.5, 250mM NaCl, 1% Igepal 
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CA-630, 10mM MgCl2, 1mM EDTA and 2% glycerol, 10μg/ml aprotinin,10μg/ml 
leupeptin, and 1mM sodium orthovanadate in the present of protease inhibitor cocktail 
(Roche). The supernatants were collected, and 0.5 ml of each extract was aliquot to 
different microfuge tube. For the controls: 5µl of GTPγS (100μM final concentration, 
as positive control) or GDP (1mM final concentration, as negative control) was added 
to 2 separate tubes, and incubated for 30 minutes at 30ºC with agitation, then the 
reactions were stopped by placing the tubes on ice and adding MgCl2 (to 60mM final 
concentration). 10 µg RAf-1 RBD agarose were subsequently added into each tube, 
and the reaction mixtures were incubated for 45 minutes at 4ºC with gentle agitation. 
The agarose beads were pelleted by contrifugation 11,000g for 1 minute at 4ºC and 
washed by MLB. Steps of contrifugation and washing were repeated 3 times, 
followed by the resuspension of agarose beads in sample loading buffer. The samples 
were boiled for 5 minutes at 95ºC and run on SDS-PAGE gel, and finally analyzed by 
western blotting. 
 
2.20. Soft Agar Assay for Colony Formation 
3% DNA grade agar was melt in microwave and cooled to 40ºC in a water bath, and 
base agar was made by mixing pre-warmed 2X DMEM with molten agar to give 0.5% 
Agar in 1XDMEM concentration. 1.5ml mixture was added into 3.5 mm Petri dish. 
For top agar, 0.7% DNA grade agar was melt in microwave and cooled to 40ºC in a 
water bath, and mixed with pre-warmed 2X DMEM in the presence of 5000cells, 
finally resulting in a 0.35% agar+ 1X DMEM+5000cells. Replicate plates were made 
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and incubated at 37ºC in humidified incubator for 2 weeks and stained with 0.5ml of 





































Chapter 3 Characterization of Endogenous TOM1-L1 Complex and 
TOM1-L1 Antibodies 
 
3.1. Endogenous TOM1-L1 is in a ~300 kDa Complex at A431 Cells. 
To investigate the characterization of endogenous TOM1-L1, I tested whether it was a 
component of a multi-protein complex in wild type A431 cells. A431 cells cytosol 
extracts were prepared and separated by Superose 6 size exclusion chromatography 
(GE). Sec23a as control protein was detected in fractions B6 to B11 and corresponded 
to a molecular mass around 300-400 kDa, which matched our lab unpublished result 
(Ong Yan Shan). Only one protein peak was detected by anti-TOM1-L1, which was 
eluted in fractions B10 to B11 and corresponded to a molecular mass of about 300 
kDa compared to control protein Sec23a (Figure 3.1). This result indicated that the 





Figure 3.1 Endogenous TOM1-L1 is in a ~300 kDa Complex.  
A: Illustration of various size proteins fractionated by Superose 6 size exclusion chromatography, total 
59 samples was collected.  
B-C: Samples eluted in B6-B10 were TCA-precipitated, and detected by SDS-PAGE and western blot 
with anti-TOM1-L1 or Sec 23 antibodies, respectively. At figure D, only one protein peak is detected 








3.2. Specificity of anti-TOM1-L1 and anti-p-TOM1-L1. 
To determine the intracellular distribution of native TOM1-L1, I generated antibodies 
against wild-type TOM1-L1 as well as the tyrosine phosphorylated form of TOM1-L1.  
Rabbit polyclonal antibodies against TOM1-L1 were raised against the C-terminal 
region (a.a. 285-476) while antibodies against tyrosine phosphorylated TOM1-L1 
(pTOM1-L1) were raised against the peptide TEAIY(phospho)EEIDAHQHKGC.  
As shown in Figure 3.2 B, the anti-TOM1-L1 recognised specifically overexpressed 
HA-TOM1-L1 but not HA-hTOM1 or HA-hTOM1-L2.  The HA-tagged protein 
migrates on SDS-PAGE as a protein specie of about 52 kDa.  The anti-TOM1-L1 
also recognises a faster migrating protein specie of about 50 kDa, which matches well 
with the predicted size of TOM1-L1.  Hence, the endogenous hTOM-L1 appears 
represented by the 50 kDa band while the HA-tagged version runs as a 52 kDa specie.  
The specificity of the antibody was further confirmed by blocking the antibody with 
GST, GST-TOM1 (300-492) or GST-TOM1-L1 (285-476) before being used to probe 
a blot containing HA-TOM1-L1.  As shown in Figure 3.2A, the antibody only fails 
to recognize HA-TOM1-L1 or the putative endogenous protein when it is blocked by 
its antigen GST-TOM1-L1 (285-476) and not when it is blocked by GST or 
GST-TOM1(300-492).  The anti-pTOM1-L1 also recognized TOM1-L1 but not 
TOM1 or TOM1-L2 (Figure 3.2C). Furthermore, when cells were starved or 
stimulated with EGF, the signal revealed by anti-TOM1-L1-pY460 was decreased and 
increased, respectively (Figure 3.2D), suggesting that this antibody has a higher 
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affinity for Tyr-phosphorylated TOM1-L1, although it also recognized the 
un-phosphorylated TOM1-L1.   
 
Figure 3.2 Characterizations of TOM1-1L1 Antibodies.  
 
A: Lysates from A431 cells either transfected (+) or not transfected (-) to express HA-tagged 
TOM1-L1 were analysed by immunoblot using rabbit antibody raised against GST-TOM1-L1(286-476) 
(upper panel) or anti-HA antibody (lower panel). The TOM1-L1 antibody was incubated with either 
GST, GST-Tom1(300-492), or GST-TOM1-L1(285-476) prior to the blotting. Detection of endogenous 
or HA-tagged TOM1-L1 was abolished by incubating the antibody with the antigen but not with GST 
or GST-Tom1(300-492). 
B: Lysates derived from A431 cells transfected with HA-tagged Tom1, TOM1-L1 or Tom1L2 were 
analyzed by immunoblot analysis with antibody against TOM1-L1 (upper panel) or anti-HA (lower 
panel).  Anti-TOM1-L1 antibody detected both endogenous and HA-tagged TOM1-L1 but not Tom1 
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or Tom1L2 (either endogenous or HA-tagged), although the HA-tagged Tom1 and Tom1L2 were 
expressed at similar levels as TOM1-L1 (lower panel).  
C: Lysates derived from A431 cells transfected with HA-tagged Tom1, TOM1-L1 or Tom1L2 were 
analyzed by immunoblot analysis with antibody against pTOM1-L1 raised against 
(456TEAIY(phospho)EEIDAHQHKG) (upper panel) or anti-HA antibody (lower panel).  
Anti-pTOM1-L1 antibody detected both endogenous and HA-tagged TOM1-L1 but not Tom1 or 
Tom1L2 (either endogenous or HA-tagged), although the HA-tagged Tom1 and Tom1L2 were 
expressed at similar levels as TOM1-L1 (lower panel). 
D: A431 cells were starved or not starved and stimulated or not stimulated with EGF, then the cell 
lysates (lowest panels) and immunoprecipitates with anti-TOM1-L1 antibodies (upper three panels) 
were analyzed by immunoblot analysis with antibody against phosphor-Tyr (upper panel), antibody 
against phosphor-TOM1-L1(second panel), and against TOM1-L1(third panel). 3% of the cell lysates 


















Chapter 4 TOM1-L1 is Tyrosine Phosphorylated by EGF, PDGF, 
and FGF via a Src/Fyn-dependent Pathway 
 
4.1. Tyrosine Phosphorylation of TOM1-L1 by Fyn Mediates its Association with 
Grb2 and PI3K-p85 
The mouse homologue of TOM1-L1, mSrcasm, has previously been reported to be 
tyrosine phosphorylated by Fyn, a Src-family tyrosine kinase (Seykora et al., 2002).  
To confirm that the human homolog is similarly phosphorylated by Fyn, HA-tagged 
TOM1-L1 was co-expressed with Fyn in 293T cells, and the cell lysates subjected to 
co-immunoprecipitation with anti-HA antibody and Western analyses.  As shown in 
Figure 4.1A, TOM1-L1 was indeed tyrosine phosphorylated in the presence of 
overexpressed Fyn, as indicated by western blotting with pTyr antibody.  
Co-expressed Fyn was required for TOM1-L1 to interact with Grb2 in a pull-down 
assay using Grb2-conjugated beads (Figure 4.1B).  The presence of Fyn also enabled 
TOM1-L1 to co-immunoprecipitate PI3K-p85 (Figure 4.1C). These results suggest 
that tyrosine phosphorylation of TOM1-L1 regulates its ability to associate with Grb2 
and p85. Unlike TOM1-L1 and TOM1-L1-SH3, TOM1-L1/Y392F and 
TOM1-L1/Y460F are both no longer able to interact with Grb2 (Figure 4.1D), 
suggesting that Fyn-catalyzed Tyr-phosphorylation of TOM1-L1 triggers interaction 
with Grb2 that is dependent of both Y460 and Y392. Indeed, TOM1-L1 binds Grb2 





Figure 4.1 Tyrosine Phosphorylation of 
TOM1-L1 by Fyn is Required for its 
Interaction with Grb2 and PI3K p85.   
A: TOM1-L1 is phosphorylated by Fyn 
but not TOM1 or TOM1-L2.  293T cells, 
transiently transfected with Myc-Fyn 
alone, or together with HA-TOM1, 
HA-TOM1-L1 or HA-TOM1-L2, were 
lysed and subjected to 
immunoprecipitation (IP) with anti-HA 
antibody.  The protein complexes were 
analysed by Western blot analysis with 
anti-pTyr antibody to detect tyrosine 
phosphorylated proteins. The inputs (3%) 
were also analysed by Western blotting 
with anti-HA and anti-Myc antibodies.  
B: TOM1-L1 associates with Grb2 in a 
phosphorylation-dependent manner.  
293T cell lysates containing 
overexpressed Myc-Fyn,  
Myc-Fyn+HA-TOM1, Myc-Fyn+HA- 
TOM1-L1 or Myc-Fyn+HA-TOM1-L2 
were incubated with GST-Grb2 
immobilised on agarose beads.  The 
protein complexes were resolved by 
SDS-PAGE followed by Western analysis 
with anti-HA antibody.  The inputs were 
also analysed by Western blotting with 
anti-HA and anti-Myc antibodies.   
C: TOM1-L1 associates with PI3K p85 in 
a phosphorylation-dependent manner.  
293T cells were transfected as in B and 
the resultant cell lysates were subjected to 
immunoprecipitation with anti-HA 
followed by Western analysis with 
anti-p85 antibody.  The inputs were also 
analysed by Western blotting with 
anti-HA and anti-Myc antibodies.  
D: TOM1-L1 associates with Grb2 in a phosphorylation-dependent manner. 293T cells were 
transfected with Myc-Fyn with HA-TOM1-L1 or various mutants. GST pull-down derived from the 
cell lysate with GST-Grb2 beads were analysed by immunoblot analysis to detect TOM1-L1 (upper 
panel). 5% of the inputs were also analysed by immunoblot with anti-HA and anti-Myc antibodies.                      
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4.2. Tyrosine Phosphorylation of TOM1-L1 by Src at the Putative SH2 Binding 
Site. 
Fyn kinase is a member of the SFK (Src family kinase), and is closely related to Src 
and Yes. Fyn and Yes can compensate for the deficiency in Src single knock out 
mouse in all tissues except osteoclasts (Stein et al., 1994). Src is a well studied kinase 
in this family and may be involved in the upstream regulator of TOM1-L1. I next 
tested if Src has the same effect on TOM1-L1.  Co-expression of HA-tagged 
TOM1-L1 with Src similarly resulted in the tyrosine phosphorylation of TOM1-L1 
(Figure 4.2A).  However, co-expression of TOM1-L1 with a dominant negative 
kinase-deficient form of Src, Src-KD, did not cause the tyrosine phosphorylation of 
TOM1-L1 (Figure 4.2B).  This suggests that the tyrosine phosphorylation of 
TOM1-L1 may be attributed specifically by Src.  To determine the 
Src-phosphorylated site on TOM1-L1, several TOM1-L1 constructs where specific 
C-terminal tyrosine residues were mutated to alanine were co-expressed with Src.  
As shown in Figuire 4.2C, Src phosphorylates TOM1-L1 specifically at Tyr460.  
This data confirmed the data for mSrcasm where the corresponding Tyr460 not 
Tyr457 (SH3 binding site), Tyr392 (Grb2 binding site) or Try441 (PI3K-p85 binding 
site) was phosphorylated by Fyn (Seykora et al., 2002). 
 
Figure 4.2 Tyrosine Phosphorylation of TOM1-L1 by Src at the Putative SH2 Binding Site.   
A: TOM1-L1 is tyrosine phosphorylated by Src but not TOM1 or TOM1-L1.  293T cells, transiently transfected 
with Src alone, or together with HA-TOM1, HA-TOM1-L1 or HA-TOM1-L2, were lysed and subjected to 
immunoprecipitation (IP) with anti-HA antibody.  The protein complexes were analysed by Western blot analysis 
with anti-pTyr antibody to detect tyrosine phosphorylated proteins. The inputs were also analysed by Western 
blotting with anti-HA and anti-Src antibodies.   
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B: tyrosine phosphorylation of TOM1-L1 by Src requires its kinase activity.  293T cells were transfected with 
constructs expressing Src+HA-TOM1-L1 or Src KD (kinase-dead Src)+HA-TOM1-L1, lysed, and then subjected 
to immunoprecipitation with anti-HA antibody.  The protein complexes were then analysed by Western blotting 
with anti-pTyr to detect tyrosine phosphorylated proteins.  The inputs were also analysed by Western blotting 
with anti-HA and anti-Src antibodies.   
C:  Src phosphorylates the putative SH2 domain of TOM1-L1.  293T cells were co-transfected with Src and the 
indicated HA-TOM1-L1 constructs. The cells were lysed and the lysates immunoprecipitated with anti-HA 
antibody.  The protein complexes were analysed by Western blotting with anti-pTyr to detect tyrosine 
phosphorylated proteins.  The inputs were also analysed by Western blotting with anti-HA and anti-Src 
antibodies. –SH3, 421LPPLP to 421LAALA mutant, mutation of putative SH3 binding site; Y460F, mutation of 
the putative SH2 binding site. 
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4.3. TOM1-L1 is Tyrosine Phosphorylated by EGF via a Src-Dependent Pathway 
and Important for Interaction with Grb2. 
Since activation of the EGF receptor is associated with activation of the Src signaling 
pathway (Luttrell et al., 1988), I next tested the ability of EGF to cause tyrosine 
phosphorylation of TOM1-L1.  When HA-TOM1-L1-expressing A431 cells were 
stimulated with EGF and the lysate subjected to immunoprecipitation with anti-HA 
antibody, HA-TOM1-L1 was indeed tyrosine-phosphorylated as revealed by Western 
analysis with the anti-phosphotyrosine antibody (Figure 4.3B).  HA-TOM1-L1 
containing a tyrosine to phenylalanine mutation at a.a. 460, however, was not 
phosphorylated in the presence of EGF (Figure 4.3B).  Hence, EGF causes 
phosphorylation of TOM1-L1 at Tyr460, the same site that was phosphorylated by 
Src (Figure 4.2C).  Unlike TOM1-L1 and TOM1-L1-SH3, TOM1-L1/Y392F and 
TOM1-L1/Y460F are both no longer able to interact with Grb2 (Figure 4.3D), 
suggesting that Src-catalyzed Tyr-phosphorylation of TOM1-L1 triggers interaction 
with Grb2 that is dependent on both Y460 and Y392. To determine if Src is indeed 
involved in the tyrosine phosphorylation of TOM1-L1 by EGF, cells transfected with 
HA-TOM1-L1 were treated with the Src inhibitor, PP1 (Hanke et al., 1996), and then 
stimulated with EGF for 5 min.  As shown in Figure 4.3C, EGF cannot cause the 
tyrosine phosphorylation of HA-TOM1-L1 in the presence of PP1.  This result 




Figure 4.3 TOM1-L1 is Tyrosine Phosphorylated by EGF via a Src-Dependent Pathway and Important for Interaction 
with Grb2.  
A: A431 cells stably 
expressing HA-tagged Tom1, 
TOM1-L1, or Tom1L2 were 
starved in culture medium 
without FBS overnight and 
then either untreated or 
treated with EGF (100ng/ml) 
for 5 min.  Cell lysates 
were immunoprecipiated 
with anti-HA antibodies and 
the precipiates were 
analyzed by immunoblot to 
detect the HA-tagged 
proteins (lower panel) or 
Tyr-phosphorylated 
proteins.  
B: A431 cells stably 
expressing TOM1-L1 (wt) 
or various mutants were 
treated with EGF (100ng/ml 
for 5 min). 
Immunoprecipitates of the 
cell lysates with 
HA-antibodies were 
analysed by immunoblot to 
detect HA-tagged proteins 
(lower panel) or 
Tyr-phosphorylated proteins 
(upper panel).   
C: A431 cells stably 
expressing TOM1-L1 were 
either untreated or treated 
with EGF in the presence or 
absence of Src kinase 
inhibitor PP1 as indicated.  
Immunoprecipitates of the cell lysates with HA-antibodies were analysed by immunoblot to detect HA-tagged 
proteins (lower panel) or Tyr-phosphorylated proteins (upper panel).  
D: A431 cells stably expressing HA-tagged Tom1, TOM1-L1, or Tom1L2 were starved in culture medium without 
FBS overnight and then either untreated or treated with EGF (100ng/ml) for 5 min.  Cell lysates were 
immunoprecipiated with anti-pTyr antibodies and the precipitates were analyzed by immunoblot to detect the 
HA-tagged proteins. 
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Next, I wanted to determine if other members of the TOM1 family are also tyrosine 
phosphorylated in the presence of EGF.  HA-TOM1, HA-TOM1-L1 and HA-TOM1- 
L2 were overexpressed in A431 cells, stimulated with EGF, lysed and 
immunoprecipitated with anti-HA antibody.  As shown in Figure 4.3A, only 
HA-TOM1-L1 was tyrosine phosphorylated when the cells were stimulated with EGF.  
Similarly, when EGF-treated cell lysates were subjected to immunoprecipitation with 
anti-phoshotyrosine antibody, only HA-TOM1-L1 was immunoprecipitated (Figure 
4.3D).  Hence, these results suggest that in the TOM1 protein family, only 
TOM1-L1 is regulated by tyrosine phosphorylation in the presence of EGF. 
 
4.4. TOM1-L1 is also Tyrosine Phosphorylated by PDGF and FGF via a 
Src-Dependent Pathway. 
I next tested if either PDGF or FGF is able to tyrosine phosphorylate TOM1-L1 since 
activation of the PDGF or FGF receptor is also associated with activation of the Src 
signaling pathway (Kypta et al., 1990, Zhan et al., 1994). NIH3T3 cells were treated 
with PDGF for 5 min followed by cell lysis and immunoprecipitation with 
anti-TOM1-L1 antibody.  On Western analysis with anti-phosphotyrosine antibody, 
TOM1-L1 was tyrosine phosphorylated (Figure 4.4A).  Specifically, TOM1-L1 
tyrosine phosphorylation in the presence of PDGF requires Tyr460 as the Y460F 
mutant was not tyrosine phosphorylated (Figure 4.4A).  The same observation was 
made when the cells were stimulated with FGF for 5 min.  As shown in Figure 4.4B, 
TOM1-L1 was phosphorylated in the presence of FGF at Tyr460.   
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To ascertain that Tyr460 phosphorylation of TOM1-L1 as stimulated by PDGF or 
FGF occurs via the Src signaling pathway, I stimulated cells deficient in Src, Yes and 
Fyn (SYF cells) (Klinghoffer et al., 1999) with PDGF or FGF and examined 
HA-TOM1-L1, immunoprecipitated by anti-HA antibody, for tyrosine 
phosphorylation.  As shown in Figure 4.4C, tyrosine phosphorylation of TOM1-L1 
was blocked in the SYF cells stimulated by either PDGF of FGF.  This observation 
suggests that TOM1-L1 can be tyrosine phosphorylated at Tyr460 by PDGF or FGF 
via the Src family of protein kinases. 
 
Figure 4.4 TOM1-L1 is also Tyrosine Phosphorylated by PDGF and FGF via a Src-Dependent 
Pathway.  
A-B: NIH 3T3 cells stably expressing 
TOM1-L1 (wt) or various mutants 
were either untreated (lane 1) or 
treated with PDGF-BB (50ng/ml for 5 
mins) (A) or FGF2 (20ng/ml for 5 
mins) (B).  Immunoprecipitates of 
the cell lysates with HA-antibodies 
were analysed by immunoblot to 
detect HA-tagged proteins (lower 
panel) or Tyr-phosphorylated proteins 
(upper panel).  
C: mouse NIH-3T3 cells or SYF cells 
(defective in Src kinases Src, Fyn and 
Yes) were either untransfected or 
transfected to express HA-TOM1-L1 
were either untreated or treated with 
PDGF-BB or FGF2.  
Immunoprecipitates of the cell lysates 
with HA-antibodies were analysed by 
immunoblot to detect HA-tagged 
proteins (lower panel) or 
Tyr-phosphorylated proteins (upper 
panel).   
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Chapter 5  TOM1-L1 Mediates the Endocytosis of EGFR 
 
5.1. EGF Stimulates Transient Association of Tyr-phosphorylated TOM1-L1 
with Activated EGFR via Grb2.   
I next examined the kinetics of EGF-stimulated Tyr-phosphorylation of TOM1-L1.  
Starved A431 cells stably expressing HA-TOM1-L1 were treated with EGF for 
various periods of time.  Cell lysates were immunoprecipitated with HA antibodies. 
The precipitates and cell lysates (as loading controls) were analyzed by immunoblot 
analysis (Figure 5.1A).  When probed with 4G10 Mab, TOM1-L1 was observed to 
be Tyr-phosphorylated after 2 min of stimulation with the maximal level of 
Tyr-phosphorylation being detected at 5 min.  After 10 min, the level of 
phosphorylated TOM1-L1 was dramatically reduced.  At 20 min and beyond, 
Tyr-phosphorylation of TOM1-L1 was no longer detected (Figure 5.1A, lower band 
of upper panel).  In addition to Tyr-phosphorylated TOM1-L1, another 
Tyr-phosphorylated protein species of about 180-200 kDa was detected by the 
phospho-Tyr-specific 4G10 monoclonal antibody in the anti-HA immunoprecipitate 
(Figure 5.1A, upper band of upper panel).  Since EGFR is about 180-200 kDa and is 
known to be Tyr-phosphorylated upon EGF stimulation with a similar kinetics (Zhang 
et al., 2005, Olsen et al., 2006), I probed the same blot with antibodies against EGFR 
and a similar pattern was observed (Figure 5.1A, middle panel).  These results 
suggest that EGF not only simulated Tyr-phosphorylation of TOM1-L1 but also 
triggered a transient association of Tyr-phosphorylated TOM1-L1 with 
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Tyr-phosphorylated (and thus activated) EGFR.  Since co-immunoprecipitation of 
EGFR with TOM1-L1 was not detected for mutant TOM1-L1/Y460Y or 
TOM1-L1/Y392F (Figure 5.1B), Tyr-phosphorylation mediated by Src family kinases 
and its subsequent ability to interact with Grb2 may be both important for TOM1-L1 
to interact with activated EGFR.  The importance of Grb2 in mediating the 
interaction of TOM1-L1 with EGFR was supported by the observation that 
EGF-induced co-immunoprecipitation of EGFR with TOM1-L1 was dramatically 
compromised in cells transfected with siRNA to knockdown the expression of Grb2 
(Figure 5.1D, Lane 3) as compared to cells transfected with non-targeting siRNA 
(Figure 5.1D, Lane 1). These results suggest that upon stimulation with EGF, EGFR 
activates Src family kinases to phosphorylate TOM1-L1 in a Y460-dependent manner, 
leading to a transient interaction between Tyr-phosphorylated TOM1-L1 and 
activated EGFR with Grb2 as a bridging factor.  
 
I have used these antibodies to study the behavior of endogenous TOM1-L1.  Upon 
stimulation with EGF, endogenous TOM1-L1 (Figure 5.1C, lower band of upper 
panel) was Tyr-phosphorylated with similar kinetics as HA-tagged TOM1-L1.  
Furthermore, Tyr-phosphorylated EGFR (Figure 5.1C, upper band of upper panel) 
was transiently co-immunoprecipitated with TOM1-L1 by the anti-TOM1-L1 
antibody (also see Figure 5.1C, middle panel) with kinetics correlating with the 
pattern of TOM1-L1 Tyr-phosphorylation.  The signals detected with the 
anti-pTOM1-L1 antibody were also transiently increased during EGF stimulation, 
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confirming that it has a higher affinity for Tyr-phosphorylated TOM1-L1 (Figure 
5.1C, third panel from the top).  These results confirmed that EGF stimulates 
transient Tyr-phosphorylation of endogenous TOM1-L1 and its interaction with 
endogenous Tyr-phosphorylated EGFR.   
 
Figure 5.1  EGF Stimulates Transient Association of Tyr-phosphorylated TOM1-L1 with Activated EGFR 
via Grb2.   
A: A431 cells stably expressing HA-TOM1-L1 were treated with EGF (100 ng/ml) for the indicted period of time.  
The cell lysates (lower two panels) and immunoprecipitates using HA antibodies (upper two panels) were analysed 
by immunoblot analysis using antibody against phosphor-Tyr (upper panel), antibody against EGFR (second 
panel), antibody against EGFR (third panel), or antibodies against HA (bottom panel).  
B: A431 cells stably expressing HA-TOM1-L1 or its mutants were treated with EGF (100 ng/ml for 5 min).   
Cell lysates were precipitated with HA antibodies and the precipitates were analysed by immunoblot analysis to 
detect HA-tagged TOM1-L1 (lower panel) or co-precipitated EGFR (upper panel).   
C: A431 cells were treated with EGF (100ng/ml) for the indicted period of time.  The cell lysates were 
immunoprecipitated with rabbit antibody against TOM1-L1 to recover endogenous TOM1-L1.  The 
immunoprecipitates were analysed by immunoblot analysis using anti-phosphor-Tyr antibody (upper panel), 
anti-EGFR antibody (the second panel), rabbit antibody that preferentially recognizes Tyr-phosphorylated 
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TOM1-L1 (the third panel). Cell lysates were also analysed to detect EGFR (the forth panel) and TOM1-L1 (the 
bottom panel) as loading controls. 
D: A431 cells either untreansfected or transfected with siRNA to knockdown Grb2 as indicated.  Cells were 
either untreated or treated with EGF (100ng/ml for 5 min).  Cell lysates were immunoprecipitated with antibodies 
against TOM1-L1 and the precipitates were analysed with antibodies against TOM1-L1, phosphor-Tyr or EGFR. 
The cell lysates were also analysed to detect Grb2 (the fourth panel), TOM1-L1 (the fufth panel) and β-tubulin 
(the bottom panel) as loading controls. 
 
  
5.2. Endogenous Localisation of TOM1-L1. 
The availability of the antibodies recognizing endogenous TOM1-L1 as well as its 
phosphorylated form enables us to determine the cellular localization of native and 
phosphorylated TOM1-L1.  When anti-TOM1-L1 was used to probe A431, NRK 
and HeLa cells in immunofluorescence studies, the protein appears present mainly in 
the cytosol compartment of all three cell types (Figure 5.2A, B). The specificity of the 
antibodies was further confirmed by blocking the antibodies with GST-TOM1-L1 
(285-476), and the antibodies failed to recognize TOM1-L1 in immunofluorescence 
studies (Figure 5.2C). This observation was confirmed by subcellular fractionation of 
A431 cells followed by detection of TOM1-L1 by Western analysis.  As shown in 
Figure 5.2D, TOM1-L1 was detected only in the cytosolic fraction of the cells. Hence, 
these observations indicate that TOM1-L1 is normally present in the cytosolic 
compartment of cells.  
 
Figure 5.2 Endogenous TOM1-L1 is Primarily Cytosolic.  
A and B: Indirect immunofluorescence microscopy of A431, NRK, and Hela cells using rabbit 
anti-TOM1-L1 or anti-pTOM1-L1 antibody, respectively. Bar. 10 µm. 
C:  Indirect immunofluorescence microscopy of A431 using rabbit anti-TOM1-L1 antibody. The 
TOM1-L1 antibody was incubated with GST-TOM1-L1(285-476) prior to the probing. Bar. 10 µm. 
 83
D: A431 cells were lysed and the lysates were fractionated into cytosol and total membrane fractions, 
which were analysed by immunoblot using antibody against TOM1-L1 (first panel), against Syntaxin 5 
(as a membrane marker, middle panel), or against RhoGDI1 (as a cytosolic marker, third panel). 
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5.3. Temporal Correlation between the Association of TOM1-L1 with Cellular 
Membranes and EGF Stimulation of A431 Cells. 
To investigate the possibility that TOM1-L1 may alter its cellular localization in 
response to activation of EGF signaling, I went on to probe A431 cells stimulated 
with EGF for increasing periods of time.  The location of tyrosine phosphorylated 
TOM1-L1 was visualized by immunofluorescence staining with anti-pTOM1-L1.  
As shown in Figure 5.3, the phosphorylated protein demonstrates a progressive 
migration from the cytosol at 0 min (Figure 5.3A) to the plasma membrane from 2 to 
10 min (Figure 5.3B-D) and finally to intracellular vesicular membranes by 20 min 
(Figure 5.3E).  The anti-pTOM1-L1 staining of intracellular vesicles was evident up 
to 1 hour of stimulation with EGF (Figure 5.3F-G).  However, after 3 hour of EGF 
stimulation, pTOM1-L1 appears to have returned to its original cytosolic staining 
pattern (Figure5.3H).  Hence, tyrosine phosphorylated TOM1-L1 appears recruited 
progressively from plasma membrane to intracellular vesicles upon activation of the 
EGF signaling pathway.   
 
Since TOM1-L1 is phosphorylated via Src in response to EGF (see above), I went on 
to examine the involvement of Src kinases in the membrane association of TOM1-L1.  
Toward this end, A431 cells were pre-treated with the Src inhibitor PP1 before 
stimulation with EGF for 30 min and examined for membrane distribution of 
TOM1-L1.  As shown in Figure 5.3I, pTOM1-L1 did not migrate to intracellular 
vesicular membranes and remained mainly cytosolic. This observation was confirmed 
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by subcellular fractionation of A431 cells followed by detection of TOM1-L1 by 
Western analysis (Figure 5.3J). Hence, tyrosine phosphorylation of TOM1-L1 via Src 
kinases that are activated by EGF signaling is essential for the migration of TOM1-L1 




Figure 5.3 Temporal Correlations Between the Association of TOM1-L1 with Cellular 
Membranes and EGF Stimulation of A431 Cells.  
A-H: A431 cells were treated with EGF (100ng/ml) for the indicted period of time.  Cells were 
analysed by indirect immunofluorescence microscopy to detect endogenous TOM1-L1. Bar. 10 µM .  
I: A431 cells were pre-treated with the Src inhibitor PP1 before stimulation with EGF for 30 min and 
examined for membrane distribution of TOM1-L1. Cells were analysed by indirect 
immunofluorescence microscopy to detect endogenous TOM1-L1. Bar. 10 µM .  
J: A431 cells were lysed and the lysates were fractionated into cytosol and total membrane fractions, 
which were analysed by immunoblot using antibody against TOM1-L1. 
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5.4. TOM1-L1 is Recruited to EGF Receptor-containing Early Endosomes in 
response to EGF. 
To determine the identity of the intracellular vesicles, which TOM1-L1 migrates into 
upon stimulation by EGF, I performed indirect immunofluorescent experiments on 
A431 cells stimulated with EGF for 30 min.  The cell were co-stained with 
anti-pTOM1-L1 and EEA1 antibodies. The latter being a marker for early endosomes 
shows that TOM1-L1 appears to be located in early endosomes in the stimulated cells 
(Figure5.4A). This result was further confirmed by co-staining the cells with LAMP1, 
a marker for late endosomes/lysosomes.  In these cases, there were no overlap in the 
staining patterns of phosphorylated TOM1-L1 and the marker LAMP1 (Figure 5.4F).  
In addition, there was a strong colocalisation between the phosphorylated TOM1-L1 
staining pattern and that of EGF receptor (Figure 5.4I).  These observations indicate 
that phosphorylated TOM1-L1 is recruited to early endosomes that also contain 
internalized EGF receptor upon stimulation by EGF.  This therefore raises the 
possibility that upon activation by EGF, TOM1-L1 is recruited into early endosomes 




Figure 5.4 TOM1-L1 is Recruited to EGF Receptor-Containing Early Endosomes in Response to 
EGF.  
A-I: A431 cells were treated with EGF (100ng/ml) for 20-25 min followed by analysis by indirect 
immunofluorescence microscopy to co-detect TOM1-L1 and respective proteins as indicated.  Bar. 10 





5.5. Mutant Forms of TOM1-L1 Defective in Tyr-Phosphorylation or Interaction 
with Grb2 Inhibit Endocytosis of EGFR. 
I next addressed the functional significance of EGF stimulated Tyr-phosphorylation of 
TOM1-L1 and its interaction with EGFR.  Firstly, I examined whether the 
expression of the various mutants of TOM1-L1 had any effect on the endocytosis and 
degradation of EGFR.  The internalization and degradation of Texas Red-EGF were 
first assessed.  Cells were incubated with Texas Red-EGF on ice for 60 min to allow 
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binding of Texas Red-EGF to EGFR on the cell surface.  After extensive washing to 
remove excess/unbound labeled EGF, cells were incubated at 37 ºC for 3 hour to 
allow its internalization and delivery to the lysosome for degradation. To visualize 
surface-bound Texas Red-EGF, cells were not incubated at 37 oC (0 hr).  Under this 
condition, A431 cells and A431 cells expressing HA-tagged TOM1-L1, 
TOM1-L1-SH3, TOM1-L1/Y460F all exhibited comparable levels of binding of 
Texas Red-EGF (Figure 5.5A, left panels), which has a characteristic surface 
appearance highlighted by the strong labeling of cell boundaries.  After incubation at 
37 ºC for 3 hour, the majority of Texas Red-EGF was essentially degraded in A431 
cells as well as A431 cells expressing HA-tagged TOM1-L1 and TOM1-L1-SH3 with 
trace amounts being detected on the plasma membrane and in intracellular punctates 
(Figure 5.5A, right panels).  However, in cells expressing TOM1-L1/Y460F, 
significant amount of Texas Red-EGF remained detectable on the plasma membrane 
and intracellular punctates, suggesting that internalization and/or degradation of 
surface-bound Texas Red-EGF was compromised in the presence of 
TOM1-L1/Y460F.  Similar blockage of endocytosis and degradation of Texas 
Red-EGF was seen in cells expressing TOM1-L1/Y392F and TOM1-L1/Y460F-SH3 
(data not shown). 
 
I next examined the degradation of endogenous EGFR induced by incubation with 
EGF by immunoblot analysis. Cells were incubated with EGF for 0 hour or 3 hour at 
37 ºC. Total cell lysates were analyzed for the levels of EGFR by immunoblotting 
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(Figure 5.5B) and quantitative analysis by densitometry (Figure 5.5C). In control 
A431 cells, about 80% of EGFR was estimated to be degraded after 3 hour at 37 ºC as 
only about 20% of EGFR was detected (second panel) in comparison with cells 
incubated with EGF for 0 hour (first panel) (lane 1).  In cells stably expressing 
HA-tagged TOM1-L1 (lane 2) and TOM1-L1-SH3 (lane 3), EGFR degradation was 
slightly but reproducibly enhanced so that around 15% EGFR was detected (p=0.1476, 
as determined by t-test).  In cells expressing HA-tagged TOM1-L1/Y460F (lane 4), 
TOM1-L1/Y460F-SH3 (lane 5) and TOM1-L1/Y392F (lane 6), EGFR degradation 
was significantly blocked as about 50% of EGFR remained detected.  These results 
suggest that TOM1-L1/Y460F, TOM1-L1/Y460F-SH3 and TOM1-L1/Y392F, which 
are no longer able to associate with activated EGFR due to defects in 
Tyr-phosphorylation or interaction with Grb2, significantly blocked 
internalization/degradation of Texas Red-EGF as well as inhibited EGF-stimulated 
degradation of EGFR. 
 
To directly define a role for TOM1-L1 in the internalization of EGFR, I have 
monitored the distribution of activated EGFR using an antibody preferentially 
recognizing Tyr-phosphorylated EGFR (this antibody also recognizes 
unphosphorylated EGFR with less efficiency) by indirect immunofluorescence 
microscopy.  Initially upon EGF stimulation, EGFR was uniformly distributed on the 
cell surface in both A431 cells and cells expressing various forms of TOM1-L1 
(Figure 5.6A, left panels).   After  stimulation  with  EGF for 20 min, EGFR was  
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Figure 5.5 TOM1-L1 Mutants Delay Degradation of EGF and EGFR.  
A: A431 cells or A431 cells stably expressing HA-TOM1-L1 or its mutants as indicated were incubated with 
Texas Red-EGF (20 ng/ml) on ice for 60 min. After washing, the cells were incubated at 37 ºC for 0 hr (left panels) 
or 3 hr (right panels).  Cells were analysed by indirect immunofluorescence microscopy to detect TOM1-L1 and 
Texas Red-EGF.  Bar. 10 µm.  
B: A431 cells or A431 cells stably expressing HA-TOM1-L1 or its mutants as indicated were incubated with EGF 
(100 ng/ml) at 37 ºC for 0 or 3 hr.  Cell lysates were analysed by immunoblot to detect EGFR at 0 hr (upper 
panel), EGFR at 3 hr (the second panel), TOM1-L1 at 3 hr (the third panel in which both endogenous TOM1-L1, 
the lower band, as well as HA-tagged TOM1-L1, the upper band, were detected), and b-tubulin at 3 hr (bottom 
panel) serving as loading control. 
C: The results from three experiments exampled in B were quantitated by densitometric analysis for EGFR levels 
at 0 and 3 hr. After being normalized against the level of β-tubulin, the average of the percentage of EGFR 
detected at 3 hr (as compared to the EGFR level at 0 hr being set as 100%) was presented. The mean ± SD of 
three independent experiments are shown.  
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distributed abundantly in intracellular vesicular structures with some being detected 
on  the  surface in  A431  cells (Figure 5.6A, panels c-d).  Similarly, EGFR was 
predominantly detected in the intracellular vesicular structures in cells expressing 
TOM1-L1 (panels g-h) or TOM1-L1-SH3 (panels k-l) with noticeably less amounts 
being detected on the surface, indicating that these forms of TOM1-L1 enhanced 
endocytosis of the EGFR.  Importantly, EGFR was predominantly detected on the 
cell surface in cells expressing TOM1-L1/Y460F (panels o-p).  The majority of 
EGFR was similarly detected on the cell surface in cells expressing TOM1-L1/Y392F 
or TOM1-L1/Y460F-SH3 (data not shown), suggesting that TOM1-L1/Y460F, 
TOM1-L1/Y392F, and TOM1-L1/Y460F-SH3 inhibited EGFR endocytosis. To 
independently and more quantitatively measure the internalization of EGFR from the 
cell surface, I monitored the internalization of surface-biotinylated EGFR in response 
to EGF (Figure 5.6B) followed by quantitative analysis by densitometry (Figure 5.6C).  
Cells were surface-biotinylated with a cleavable biotin to biotinylate surface-exposed 
proteins such as the EGFR and TfR.  After extensive washing, biotinylated EGFR 
was stimulated with EGF to initiate internalization at 37 ºC for various periods of time.  
Cells were then quickly chilled on ice to stop additional endocytosis at various time 
points and then treated with membrane-impermeable reducing agents to remove biotin 
attached to surface-exposed EGFR in a process referred to as surface stripping.  The 
biotin attached to EGFR molecules that have already been internalized is resistant to 
this surface stripping.  The biotinylated EGFR can be retrieved by 
straptavidine-beads  for detection by  immunoblot.  In this assay,  the amount of  
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Figure 5.6 Mutant TOM1-L1 Delayed EGF-Induced Endocytosis of EGFR.  
 
A: A431 cells or A431 cells stably expressing HA-tagged TOM1-L1 or its mutants as indicated were incubated 
with EGF (100 ng/ml) followed by incubation at 37 ºC for 0 min (left panels) or 20 min (right panels) and analysed 
by indirect immunofluorescence microscopy to detect TOM1-L1 and EGFR. Bar. 10 µm.  
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B: A431 cells or A431 cells stably expressing HA-tagged TOM1-L1 or its mutants as indicated were 
surface-biotinylated with sulfo-NHS-SS-biotin.  After incubation at 37 ºC for the indicated period of time, 
surface-exposed biotin was removed by stripping in reducing buffer.  Cell lysates were incubated with 
streptavidin-beads to recover biotinylated proteins that have been endocytosed (and thus are inaccessible to the 
surface stripping).  The precipitates were analysed by immunoblot to detect EGFR. The amount of biotinylated 
EGFR that is resistant to surface stripping is a reflection of the amount of EGFR that has been endocytosed.  
C: The results from three experiments exampled in B were quantitated by densitometric analysis. Each signal is 
normalized against the level of β-tubulin detected at each time point (not shown). Values are expressed as ratio 
of signal at each time point to signal detected at 0 min being set as 100%. The mean ± SD of three independent 
experiments are shown. 
 
biotinylated EGFR that is resistant to surface stripping serves as a quantitative 
measure of the amount of internalized EGFR.  Using this approach, essentially all 
surface-biotinylated EGFR was sensitive to the surface stripping at the beginning of 
EGF stimulation (lane 2).  Within 2 min of stimulation, about 60% of EGFR had 
become resistant to surface stripping in A431 cells (lane 3), suggesting that the 
majority of EGFR had been sequestered into clathrin-coated vesicles that were no 
longer accessible to the externally applied reducing agents.  The amount of 
internalized EGFR increased gradually over 5-20 min (lanes 4-5) with more than 95% 
of biotinylated EGFR resistant to surface stripping after 20 min of internalization 
(lane 6).   Similar kinetics of endocytosis were observed with cells expressing 
TOM1-L1 or TOM1-L1-SH3.  In cells expressing TOM1-L1/Y460F, the majority 
(about 80%) of EGFR remained sensitive to surface stripping after 2 min of 
stimulation because only around 20% of EGFR becoming resistant to the stripping.  
The amount of internalized EGFR increased gradually over 5-20 min period with 
about 70% of EGFR being internalized after 20 min of stimulation.  Similar delay of 
EGFR endocytosis was observed in cells expressing TOM1-L1/Y392F or 
TOM1-L1Y460F-SH3 (Figure 5.6C).  Hence, the most dramatic reduction of 
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internalization of EGFR occurred at 2 min with 60% in control cells (or cells 
expressing TOM1-L1 or TOM1-L1-SH3) compared to 20% in cells expressing 
TOM1-L1/Y460F, TOM1-L1/Y392F or TOM1-L1Y460F-SH3 being internalized. 
This suggests that TOM1-L1 plays a crucial role in the very early events of EGFR 
endocytosis when activated EGFR is sorted and sequestered into clathrin-coated 
vesicles.  During this process, TOM1-L1/Y460F, TOM1-L1/Y392F or 
TOM1-L1Y460F-SH3 acted like dominant-negative mutants to inhibit the function of 
endogenous TOM1-L1.  These results suggest that TOM1-L1 is involved in the early 
events of sorting and sequestering of activated EGFR into clathrin-coated vesicles to 
mediate endocytosis. 
 
5.6. siRNA-Mediated Knockdown of TOM1-L1 Inhibits Endocytosis of EGFR. 
To independently verify a role for TOM1-L1 in endocytosis, I used siRNA-mediated 
knockdown to reduce the expression of endogenous TOM1-L1 and to examine the 
consequence on EGFR degradation (Figure 5.7A and B) and endocytosis (Figure 5.7C 
and D).  After stimulation with EGF for 3 hour, about 80% of EGFR was degraded 
in cells transfected with either non-targeting siRNA or cells treated with siRNA 
targeting GAPDH (Figure 5.7A, lanes 1-2).  However, EGFR degradation was 
compromised in cells transfected with siRNA targeting TOM1-L1 with only 50% of 
EGFR being degraded (Figure 5.7A, lane 3).  The endocytosis of surface 
biotinylated EGFR was also monitored by surface biotinylation and stripping in 
control and siRNA tranfected cells (Figure 5.7C and D).  In cells transfected with the 
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non-targeting siRNA or siRNA for GAPDH, about 60% of EGFR was internalized 
after 2 min of EGF stimulation (lane 3).  However, the majority (about 80%) of 
EGFR was not internalized in cells transfected with TOM1-L1 siRNA as only 20% 
biotinylated EGFR was protected from surface stripping.  The kinetics of EGFR 
internalization in cells treated with TOM1-L1 siRNA (Figure 5.7D) were similar to 
that observed in cells expressing dominant-negative mutants of TOM1-L1 as 
described above.  In order to verify that the observed defect in EGFR endocytosis is 
due to the silencing of TOM1-L1 by its siRNA, I examined the ability of 
RNAi-resistant TOM1-L1 cDNA to restore the defect of endocytosis.  Significantly, 
the defect of EGFR endocytosis in TOM1-L1 siRNA transfected cells could be 
significantly rescued by siRNA-resistant cDNA encoding mouse TOM1-L1 (Figure 
5.7E, lane 3) but not by cDNA encoding human TOM1 (Figure 5.7E, lane 4).  These 
results suggest that endogenous TOM1-L1 plays an important and specific role in the 
early events of sorting/sequestering of activated EGFR into clathrin-coated vesicles 
for endocytosis. 
 
Figure 5.7 Knockdown of TOM1-L1 Delayed EGF-Induced Degradation and Endocytosis of EGFR. 
 A: A431 cells were transfected with siRNA pools for TOM1-L1, GAPDH (as a control) or control SiRNA 
(Non-targeting Pool).  Cells were incubated with EGF (100 ng/ml) at 37 ºC for 0 or 3 hr.  Cell lysates were 
analysed by immunoblot to detect EGFR at 0 hr (upper panel), EGFR at 3 hr (the second panel), TOM1-L1 at 3 hr, 
and GAPDH at 3 hr (bottom panel) serving as loading control. 
B: The results from three experiments exampled in A were quantitated by densitometric analysis for EGFR levels 
at 0 and 3 hr. After being normalized against the level of β-tubulin (not shown), the average of the percentage of 
EGFR detected at 3 hr (as compared to the EGFR level at 0 hr being set as 100%) was presented. The mean ± 
SD of three independent experiments are shown.  
C: A431 cells transfected with siRNA pools for TOM1-L1, GAPDH (as a control) or control SiRNA 
(Non-targeting Pool) were surface-biotinylated with sulfo-NHS-SS-biotin.  After incubation at 37 ºC for the 
indicated period of time, surface-exposed biotin was removed by stripping in reducing buffer.  Cell lysates were 
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incubated with streptavidin-beads to recover biotinylated proteins that have been endocytosed, which were 
analysed by immunoblot to detect EGFR.  
D: The results from three experiments exampled in C were quantitated by densitometric analysis. Each signal is 
normalized against the level of β-tubulin detected at each time point (not shown). Values are expressed as ratio 
of signal at each time point to signal detected at 0 min being set as 100%. The mean ± SD of three independent 
experiments are shown.  
E: A431 cells were transfected with siRNA pools for TOM1-L1 or control SiRNA (Non-targeting Pool) . The cells 
were then transduced with retrovirus to express RNAi-resistant mouse TOM1-L1 or mouse Tom1 to examine the 
rescuing ability in terms of internalizing EGFR as measured by surface biotinylation, endocytosis and surface 
stripping assay.  The amount of biotinylated EGFR at 0 min is shown in first panel whereas the amount of 
biotinylated EGFR endocytosed after 2 min is shown in the second panel.  The cell lysates were also analysed by 
immunoblot to detect TOM1-L1, Tom1, total EGFR and b-tubulin as indicated (the bottom 4 panels).   
F: The results from three experiments exampled in E were quantitated by densitometric analysis. Each signal is 
normalized against the level of β-tubulin detected at 0 or 2 min. Values are expressed as ratio of signal 2 min to 
that detected at 0 min being set as 100%. The mean ± SD of three independent experiments are shown. As 
shown, defect of EGFR endocytosis due to RNAi of TOM1-L1 can be rescued by exogenous mouse TOM1-L1 but 
not mouse Tom1.  
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Chapter 6 The C-Terminal Tail of Tom1-L1 Harbors a Novel 
Clathrin-Interacting Motif Important for Mediating EGFR 
Endocytosis. 
 
6.1. The C-terminal Tail of TOM1-L1 Harbors a Novel Clathrin-interacting 
Motif. 
Our lab and others have shown previously that TOM1 contains a well-defined 
clathrin-binding motif in the C-terminal region (Yamakami et al., 2003; Seet and 
Hong, 2005); and that TOM1-L1 and TOM1-L2 may also bind clathrin through their 
C-terminal tails (Katoh et al., 2006).  I attempted to define a region of TOM1-L1 
necessary for interaction with clathrin as assessed by GST-pull down experiments 
using various fusion proteins of TOM1-L1 (depicted schematically in Figure 6.1A) to 
retrieve clathrin heavy chain (CHC).  GST-TOM1-L1 (316-476) was able to bind 
and retrieve CHC (Figure 6.1B, lane 3 as compared to lane 1) indicating that this 
region was sufficient for effective CHC interaction. Truncation experiments revealed 
that the region between residue 316 and 419 was not important for interaction with 
CHC because GST-TOM1-L1 (420-476) was able to retain CHC just as efficiently 
(lane 7) as GST-TOM1-L1(316-476) (lane 3), suggesting that the 57-residue 
C-terminal tail (residue 420-476) is responsible for interaction with CHC.  This 
region does not contain a conventional clathrin-binding motif (Dell'Angelica 2001, 
Drake andTraub, 2001, Miele et al., 2004), suggesting novel structural determinants  
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Figure 6.1 TOM1-L1 Contains a Novel Clathrin-Binding Motif  
A: Illustration of various C-terminal fragments of TOM1-L1 fused to GST.  
B-E: various C-terminal fragments of GST-TOM1-L1 fused to glutathione-Sepharose beads were incubated with 
A431 cytosol. The beads were washed and bound proteins and input were resolved by SDS-PAGE. Immunoblot 
analysis was performed with anti-clathrin heavy chain antibody (upper panel). GST and GST-fusion proteins were 
stained by Coomassie bule as a control for levels of fusion proteins used in pull-down experiments (bottom panel).  
F: Schematic diagram of the chimeric construct HA-TOM1-L1-PX which the PX domain from SNX3 was fused to 
C-terminal of the full-length TOM1-L1 coding sequence.  
G: A431 cells were transfected with HA-TOM1-L1-PX followed by analysis by indirect immunoflurescence 
microscopy to co-detect HA-TOM1-L1-PX and Clathrin. Bar. 10 µM.   
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within the 57-residue tail of TOM1-L1 that determine its interaction with clathrin. 
Another set of deletion mutants of GST-TOM1-L1, truncation from the C-terminus, 
revealed that the region encompassing residues 286-450 was able to interact with 
CHC, whereas the fragment consisting of residues 286-441 was defective in 
interaction with CHC (Figure 6.1C).  Together, these observations narrowed the 
critical clathrin-binding residues down to the region comprising residues 420-450.  
Using GST-TOM1-L1 (286-476) as the framework, I performed site-directed 
mutagenesis in four stretches (4 residues each) and identified the 447FDPL450 motif as 
important for TOM1-L1 to interact with CHC. The region centered at FDPL motif 
does not share sequence homology with consensus clathrin-binding boxes, suggesting 
that this is indeed a novel clathrin-binding motif. 
 
To confirm that TOM1-L1 is indeed able to recruit clathrin in vivo, I set up 
experiments based on an exogenously expressed form of TOM1-L1 whose targeting to 
early endosomes is autonomous. This endosomal-associated TOM1-L1 is generated 
by fusing TOM1-L1 to the PX domain of SNX3 at its C-terminus. The PX domain 
binds specifically to phosphatidylinositol 3-phosphate (Xu et al., 2001). When 
overexpressed in A431 cells and examined by immunofluorescence analysis, the 
HA-tagged TOM1-L1 chimera (HA-TOM1-L1-PX) was able to cause 
aggregation/fusion of vesicular. Indeed, overexpression of HA-TOM1-L1-PX was 
able to recruit endogenous clathrin heavy chain to vesicular structures, as assessed by 
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immunofluorescence analysis (Figure 6.1G). This result confirmed that TOM1-L1 has 
the ability to recruit clathrin. 
 
6.2. TOM1-L1’s Clathrin Binding Motif is Important for its Role in Mediating 
EGFR Endocytosis. 
In order to establish that TOM1-L1 interaction with clathrin is pivotal in mediating 
EGFR endocytosis, I performed rescue experiments in A431 cells in which 
endogenous human TOM1-L1 was knocked-down.  Mouse cDNAs (which are 
resistant to siRNA targeting human TOM1-L1) encoding wild type or various mutants 
of mouse TOM1-L1 were introduced into the siRNA-treated A431 cells.  
Internalization of surface biotinylated EGFR was assessed at 2 min stimulation with 
EGF. As shown in Figure 6.2A and quantified in Figure 6.2B, TOM1-L1 
siRNA-treated A431 cells internalized about 20-30% EGFR (Lane 2) compared to 
50-60% of EGFR being internalized in control cells (Lane 1). When mouse TOM1-L1 
was introduced by retroviral infection into the knocked-down cells, internalization of 
EGFR was rescued significantly, in that about 40-50% of EGFR was now internalized 
(Lane 3).  When the clathrin-binding 446FDPL449 motif was mutated in mouse 
TOM1-L1, the mutant failed to rescue the endocytosis of EGFR in the knocked-down 
cells (Lane 4), suggesting that interaction with CHC is crucial for TOM1-L1 to 
mediate the early event of endocytosis from the cell surface.  Furthermore, mouse 
mutants equivalent to human TOM1-L1/Y460F or TOM1-L1/Y392F also failed to 
rescue the defect of endocytosis of EGFR (Lanes 6 and 7, respectively) in the 
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knocked-down cells, consistent with the conclusions derived from studies using A431 
cells expressing various mutants of TOM1-L1.  These results suggest that both 
interaction with clathrin as well as Tyr-phosphorylation-mediated association with 
EGFR are important for TOM1-L1 to mediate endocytosis of EGFR in response to 
EGF stimulation. 
Figure 6.2 TOM1-L1’s Clathrin Binding Motif is Important for its Role in Mediating EGFR Endocytosis   
A: A431 cells were transfected 
with siRNA for TOM1-L1. The 
cells were then transduced with 
retrovirus to express 
RNAi-resistant mouse TOM1-L1 
and its various mutants to rescue 
the function of endogenous 
TOM1-L1 in terms of 
internalizing EGFR.  As shown, 
defect of EGFR endocytosis due 
to RNAi of TOM1-L1 can be 
rescued by exogenous mouse 
TOM1-L1 and 
TOM1-L1-DLQP434 AAA but 
not by TOM1-L1-FDPL446AAA 
(which is defective in interaction 
with clathrin), TOM1-L1-Y457F 
(which is equivalent to human 
TOM1-L1-Y460F defective in 
Tyr-phosphorylation), or 
TOM1-L1-Y392F (which is 
defective in interaction with 
Grb2).   
B: Quantitative analysis by 
densitometric analysis and each 
signal is normalized against the 
corresponding signal from β
-tubulin at the respective 
incubation times. Values are expressed as percentage of signal at 2 min relative to 0 min. The mean ± SD of 
three independent experiments are shown. TOM1-L1 KD: p=0.00198; TOM1-L1 KD + mouse TOM1-L1: 
p=0.10369; TOM1-L1 KD + mouse TOM1-L1 EDLP446AAAA: p=0.00168; TOM1-L1 KD + mouse TOM1-L1 
DLQP434AAAA: p=0.06710; TOM1-L1 KD + mouse TOM1-L1 Y457Y: p=0.00093; TOM1-L1 KD + mouse 
TOM1-L1 Y392F: p=0.00136, as determined by t-test. 
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6.3. Effect of Depletion of AP2, Clathrin, Cbl, Grb2 or TOM1-L1 on EGFR and 
TfnR Endocytosis. 
Figure 6.3 shows effects of each of 4 proteins (AP2, clathrin, Cbl, and TOM1-L1) 
individually on EGFR and TfR internalization. Knock down of clathrin heavy chain 
caused the largest reduction of internalization rates of both TfnR and EGFR. The 
depletion of AP2 α subunit strongly inhibits the uptake of TfnR, but has little effect 
on the uptake of EGFR.  However, the down-regulation of Cbl, Grb2 or TOM1-L1 
had significant inhibitory effect on the internalization rates of EGFR, but did not 
affect the endocytosis of TfnR. This indicated that Clathrin is involved in both EGFR 
and TfnR internalization, while AP2 regulates the endocytosis of TfnR and Cbl, Grb2 
and TOM1-L1 mediate mechanism of EGFR internalization. 
 
Figure 6.3 Effects of Proteins Depletion on EGFR and TfnR Endocytosis.  
A: A431 cell were transfected with siRNA targeting AP-2α, clathrin heavy chain, c-Cbl, TOM1-L1, 
or control siRNA.  The cells were then surface-biotinylated with sulfo-NHS-SS-biotin. After washing 
and quenching free sulfo-NHS-SS-biotin, cells were stimulated with EGF (100 ng/ml) at 37 ºC for 2 
min to induce endocytosis. Surface-exposed biotin was removed by stripping in reducing buffer. Cell 
lysates were incubated with streptavidin-beads to recover biotinylated proteins, which were analysed 
by immunoblot to detect the total amount of biotinylated EGFR at 0 min (first panel), the amount of 
biotinylated EGFR endocytosed after 2 min (second panel), the total amount of biotinylated TfR at 0 
min (third panel), and the amount of biotinylated TfR endocytosed after 2 min (forth panel). 3% inputs 
were also analysed by immunoblot to detect the proteins indicated (bottom 5 panels) as loading control. 
Knockdown of clathrin, c-Cbl and TOM1-L1 but not AP-2α reduced the endocytosis of EGFR, while 
knockdown of AP-2a and clathrin but not c-Cbl or TOM1-L1 reduced endocytosis of TfR.  
B: The amount of total biotinylated EGFR and TfR at 0 min as well as those endocytosed after 2 min 
were quantitated by densitometric analysis and normalized against the levels of β-tubulin. The 
average of three independent experiments expressed as the percentage of the amount of endocytosed at 
2 min relative to the total amount at 0 min was shown. The mean ± SD of three independent 
experiments are shown. In EGFR endocytosis, AP-2α KD: p=0.03841; Clathrin KD: p=0.00025; Cbl 
kD: p=0.00054; TOM1-L1 KD: p=0.00030. In TfR endocytosis, AP-2α KD: p=0.00145; Clathrin KD: 








Chapter 7 TOM1-L1 Interacts with Ubiquitin, Hrs and STAM, and 
Mediates Degradation of EGFR 
 
7.1. TOM1 Family Proteins Interact with Ubiquitin. 
It was reported that TOM1 interacted with Tollip, clathin and ubiquitin (Yamakami, et 
al., 2003). To investigate whether TOM1 family proteins associate with ubiquitin, I 
carried out immunoprecipitation and pull-down experiments. Myc-ubiquitin alone or 
with HA-TOM1 family proteins were overexpressed in 293T cells, and were lysed 
and subjected to immunoprecipitation (IP) with anti-HA antibody.  The protein 
complexes were analysed by Western blot analysis with anti-ubiquitin antibody to 
detect TOM1 family proteins (Figure 7.1A). The result showed that all TOM1 family 
proteins were ubiquitinated. To confirm this data, in vitro pull-down assay was 
performed. 293T cells, transiently transfected with HA-TOM1, HA-TOM1-L1, 
HA-TOM1-L2, HA-Rab5 (as negative control), HA-Hrs (as positive control) or 
pDHAneo plasma alone, were lysed and incubated with ubiquitin immobilised on 
agarose beads. The protein complexes were resolved by SDS-PAGE followed by 
Western analysis with anti-HA antibody (Figure 7.1B). Ub-agarose beads pulled 
down all TOM1 family proteins. Interesting, compared to the input, among the TOM1 




Mono-ubiquitination can serve as a signal for cargo sorting to MVB (Hicke 2001, 
Marchese and Benovic, 2001, Shenoy et al., 2001), and TOM1 forms a complex with 
Tollip and recruits ubiquitin-conjugated proteins onto early endosomes (Katoh et al., 
2004). So it will be interesting to investigate the function of TOM1-L1 on the 
endosomal sorting of EGFR. 
 




A: 293T cells, transiently transfected with 
Myc-ubiquitin alone, or together with 
HA-TOM1, HA-TOM1-L1 or 
HA-TOM1-L2, were lysed and subjected to 
immunoprecipitation (IP) with anti-HA 
antibody.  The protein complexes were 
analysed by Western blot analysis with 
anti-Ubiquitin antibody to detect tyrosine 
TOM1 family proteins. The inputs (8%) 
were also analysed by Western blotting 
with anti-HA and anti- β -tubulin 
antibodies.  
B: 293T cell lysates containing 
overexpressed HA-TOM1, HA- TOM1-L1, 
HA-TOM1-L2, HA- Rab5 (as negative 
control), HA-Hrs (as positive control) or 
plasma alone were incubated with 
Ubiquitin immobilised on agarose beads.  
The protein complexes were resolved by 
SDS-PAGE followed by Western analysis 
with anti-HA antibody.  The inputs were 
also analysed by Western blotting with 





7.2. TOM1-L1 Interacts with Hrs, STAM. 
My previous data showed that TOM1-L1/Y460F, TOM1-L1/Y460F-SH3 and 
TOM1-L1/Y392F significantly blocked internalization and degradation of Texas 
Red-EGF as well as inhibited EGF-stimulated degradation of EGFR. To further 
investigate the function of TOM1-L1 in EGFR degradation pathway, I examine 
whether TOM1-L1 can interact with the components of MVB sorting machinery such 
as Hrs or STAM. HA-tagged TOM1-L1 was expressed in A431 cells and treated with 
EGF for various periods of time, then the cell lysates subjected to 
co-immunoprecipitation with anti-HA antibody and Western analyses. When probed 
with anti-Hrs, or STAM, endogenous Hrs or STAM was detected in the blot (Figure 
7.2A). More interestingly, no significantly difference was detected in different 
EGF-stimulation time points. It suggests that the interaction between TOM1-L1 and 
Hrs or STAM is not dependent on Tyr-phosphorylation of TOM1-L1. Moreover, in 
Hrs knockout or STAM 1/2 knockout cell (from Dr. Sugamura), TOM1-L1 still 
associates with STAM or Hrs, respectively (Figure 7.2B), suggesting that the 
TOM1-L1 interaction with Hrs or STAM is independent on each other. The 
interactions of TOM1-L1 with Hrs and TSG101 were also confirmed in yeast 
two-hybrid system (Puertollano, 2005).  
 
 
Figure 7.2 TOM1-L1 Interacts with Hrs, STAM   
A: A431 stable overexpressed HA-tagged TOM1-L1, were straved over night and stimulated by EGF or not, 
then lysed and subjected to immunopreciptation (IP) with ant-HA antibody. The protein complexes were 
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analysed by Western blot analysis with anti-HA, anti-Hrs and anti-STAM antibodies. The input were also 
analysed by western blotting with anti-β-tubulin, andti-Hrs and anti-STAM antibodies.  
B: A431, STAm ½ knock-out, Hrs knock-out and Hrs rescure cells stable overexpressed HA-Tagged 
TOM1-L1 were lysed and subjected to immunopreciptation (IP) with ant-HA antibody. The protein 
complexes were analysed by Western blot analysis with anti-HA, anti-Hrs and anti-STAM antibodies. The 
input were also analysed by western blotting with anti-β-tubulin, andti-Hrs and anti-STAM antibodies.  
 
 
7.3. Hrs Recruits TOM1-L1 to Endosomes. 
To further understand the relation between TOM1-L1 and MVB sorting machinery, I 
examined whether TOM1-L1 would be recruited to endosomes by Hrs. I have used 
the anti-TOM1-L1-pY460 antibody in indirect immunofluorescence microscopy 
(Figure 7.3). In over-expression HA-Hrs A431 cells, endogenous TOM1-L1 was 
enriched in punctuate structures characteristic of endosomes from cytosol, which were 
labeled with Hrs, by immunofluorescence microscopy. This suggests that TOM1-L1 




Figure 7.3 Effect of Overexpression of HA-tagged Hrs on TOM1-L1 Localization Analyzed by 
Immunoflurescence Microscopy.  
A-C: A431 cells were transfected with HA-tagged Hrs. 16 hrs after transfection, cells were fixed, 






7.4. Knockdown of both TOM1-L1 and Hrs further Delays EGFR Degradation. 
My previous data suggests that TOM1-L1 was also involved in MVB sorting 
machinery. To investigate this hypothesis, I double knockdown TOM1-L1 and Hrs. In 
the double TOM1-L1 and Hrs knockdown A431 cells, about 45% of the EGFR was 
degraded at 3hour after EGF treatment, whereas about 60% of the EGFR was 
degraded at 3hour in single knock down either TOM1-L1 or Hrs alone, and compared 
to wild type A431, about 85% of the EGFR was degraded at 3hour (Figure 7.4A and 
B). These results together with previous data (Figure 5.5 and 5.7) strongly indicate 
that TOM1-L1 cooperates with Hrs in mediating EGFR degradation. 
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Figure7.4 Simultaneous Knockdown of Both TOM1-L1 and Hrs Causes a Delay in EGFR 
Greater than Knockdown of either TOM1-L1 or Hrs Alone.  
 
 
A: A431 cells were transfected with TOM1-L1 siRNA alone, Hrs siRNA alone, both TOM1-L1 and 
Hrs siRNA, or with control siRNA oligos. After 2 days, were incubated with Texas Red-EGF on ice 
followed by incubation at 37 ºC for 0 hour or 3 hour, and lysed and analyzed by immunoblotting with 
antibodies against EGFR, Hrs, TOM1-L1 and actin.  
B: The results from three experiments exampled in A were quantitated by densitometric analysis for 
EGFR levels at 0 and 3 hour. After being normalized against the level of actin (not shown), the average 
of the percentage of EGFR detected at 3 hour (as compared to the EGFR level at 0 hour being set as 
100%) was presented. The mean ± SD of three independent experiments are shown. Hrs KD: 





Chapter 8 TOM1-L1 is a Negative Regulator in Src Kinase Signaling 
 
8.1. TOM1-L1 Inhibits the Activation of Ras upon EGF Stimulation. 
It was reported that in Src signal transduction pathways TOM1-L1 was a negative 
regulator of Src activation and downstream DNA synthesis in the presence of PDGF 
(Franco et al., 2006). To further define its role in Src signal transduction pathways, I 
investigated the activation level of Ras by a commercially available Ras activity assay 
kit (Upstate biotechnology), in which only activated Ras-GTP can be pulled down by 
GST-Raf1-RBD. Upon EGF 10 mins stimulation, Ras activation level was decreased 
in wild type over-expression TOM1-L1 A431 cell, whereas its level was increased in 
TOM1-L1 Y460F or Y392F over-expression A431 cells compared to control wild 
type A431 cells. The result reveals that wild type TOM1-L1 inhibits the activation of 
Ras upon EGF stimulation, whereas mutant TOM1-L1 enhances activation of Ras, 
suggesting that the TOM1-L1’s phosphorylation and the association with Grb2 is 
essential for TOML1-L1 regulation of Ras activation. However, the molecular 
mechanisms by which TOM1-L1 mediate the activation of Ras is not well understood. 
In addition, one thing is quite interesting in my results. Although in input blot only 
one band of Ras can be detected, in pull-down blot two bands of Ras can be detected 
(Figure 8.1). One explanation is that two types of isoform Ras are enriched and 
detected after pull-down, whereas one is very rare in cell lysates and cannot be 




Figure 8.1 TOM1-L1 Inhibits the Activation of Ras upon EGF Stimulation.   
A431 cells stably expressing TOM1-L1 (wt) or various mutants were treated with EGF (100ng/ml for 
10 min), and GDP (as negative control) or GTP (as positive control) was added in 2 wild A431 cell. 
Cell lysates were pulled down with GST-Raf1-RBD and analyzed by immunoblot to detect activation 




8.2. TOM1-L1 Inhibits the Colony Formation in A431 Cells. 
It was shown that TOM1-L1 is a negative regulator of Src mitogenic signaling 
pathway (Franco et al., 2006).  To investigate the TOM1-L1 effect on cell colony 
formation, I performed the soft agar assay experiments. The over-expression of 
TOM1-L1Y460F or Y392F A431 cells produced the most colonies, the 
over-expression wild type TOM1-L1 A431 cells produced the fewest, and the wild 
type A431 was in the middle (Figure 8.2). Thus, the TOM1-L1 is a negative regulator 
in producing invasive and migrating colonies. 
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Figure 8.2 TOM1-L1 Inhibits the Colony Formation in A431 Cells.  
A-C: 5000 A431 cells stable expression of plasma, HA-TOM1-L1 or HA-TOM1-L1 Y460F were 
cultured in soft agar assay plates. After 2 weeks, these plates were stained with 0.5ml of 0.005% 

































Chapter 9 Discussion 
 
Although the AP-2 adaptor complex is the major adaptor important for endocytosis of 
diverse surface proteins, several independent lines of evidence have clearly shown 
that endocytosis of EGFR is primarily mediated by an AP-2-independent but 
clathrin-dependent process (Conner and Schmid, 2003, Lakadamyali et al., 2006, 
Motley et al., 2003, Nesterov et al., 1999, Traub, 2003). These studies have raised the 
challenging question of which adaptor is responsible for bridging EGFR with the 
endocytic machinery for efficient sorting/sequestering of activated EGFR into the 
endocytic vesicles.  The interaction of this candidate adaptor with EGFR is expected 
to be regulated and should coincide with activation of EGFR by its ligand.   
 
My studies indicate that TOM1-L1 clearly fulfills these criteria to qualify as the long 
sought-after adaptor for EGFR endocytosis. The evidence is clear from several 
observations. Firstly, TOM1-L1 is transiently associated with activated EGFR during 
the very early events of EGF stimulation. This interaction depends on 
Tyr-phosphorylation of TOM1-L1 via EGFR-activated Src kinases and is likely to be 
mediated by Grb2 as a bridging protein.  Secondly, TOM1-L1 harbors a novel 
clathrin-interacting motif that is not only essential for interaction with clathrin but 
also important for exogenous TOM1-L1 to functionally rescue endocytosis of EGFR 
in TOM1-L1 knocked-down cells. This dual interaction enables TOM1-L1 to 
transiently bridge activated EGFR with clathrin and the endocytic machinery for 
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efficient segregation of EGFR into the endocytic vesicle. Thirdly, upon EGFR 
activation, TOM1-L1 is rapidly recruited from the cytosol to the plasma membrane 
and redistributes with EGFR into the early endosome – consistent with and indicative 
of interaction between TOM1-L1 with EGFR.  
 
In support of the data derived from the biochemical and morphological studies, I was 
able to demonstrate functionally that TOM1-L1 is important for EGFR endocytosis.  
Firstly, mutants incapable of interaction with activated EGFR due to a defect in 
Tyr-phosphorylation (such as TOM1-L1/Y460F) or interaction with Grb2 
(TOM1-L1/Y392F) behave like dominant negative mutants as they potently inhibited 
EGF-stimulated endocytosis of EGFR and its degradation.  Secondly, 
RNAi-mediated knockdown of endogenous TOM1-L1 also inhibits EGF–stimulated 
EGFR endocytosis and degradation.  Importantly, exogenous TOM1-L1 but not 
TOM1 was able to significantly rescue the endocytosis of EGFR in these 
knocked-down cells. This system also allowed us to demonstrate that the 
clathrin-interacting motif and motifs responsible for interaction with activated EGFR 
are essential for exogenous TOM1-L1 to rescue the endocytosis of EGFR.  These 
results clearly revealed that residues/motifs of TOM1-L1 important for interaction 
with EGFR as well as interaction with clathrin are crucial for its role in mediating 
endocytosis of EGFR.  This correlation between protein-protein interaction and an 
obligatory role for TOM1-L1 in endocytosis is further evidence for, and also 




















































































































































































































































































































































































































































































































































































































endocytosis of EGFR. Consistent with the role of Grb2 in mediating interaction of 
Tyr-phosphorylated TOM1-L1 with activated EGFR, knockdown of Grb2 
significantly inhibits endocytosis of EGFR in addition to abrogating interaction of 
TOM1-L1 with EGFR (Figure 5.1 D) (Huang et al., 2005, Jiang et al., 2003). These 
results allow us to propose a working model for TOM1-L1 to act as a regulated 
adaptor in mediating EGF-stimulated endocytosis of EGFR (Figure 9.1). Upon EGFR 
activation by ligand binding, Src kinases are activated and mediate Y460 
phosphorylation of TOM1-L1.  Y460 phosphorylated TOM1-L1 is then recruited to 
the activated EGFR via Grb2 as a linker.  TOM1-L1 will then recruit clathrin 
through its novel clathrin-binding motif and this likely triggers the recruitment of 
other endocytic machinery components to initiate the sorting/segregation of activated 
EGFR into the clathrin-coated buds – ensuring that EGFR is efficiently internalized 
into the endocytic vesicle.   
 
It is noteworthy that TOM1-L1 is associated with the membrane and subsequently 
enriched in the early endosome with EGFR during receptor endocytosis via 
clathrin-coated vesicles. This was observed in spite of the fact that Y460 of TOM1-L1 
is dephosphorylated during this 20-30 min period. One possibility is that early 
endosome-associated TOM1-L1 engages in interactions with other proteins such as 
Hrs and TSG101 that enable it to stay on the membrane; and that this endosomal 
TOM1-L1 participates in the efficient segregation of EGFR in the maturing endosome 
to form the multivesicular body (MVB) (late endosome) for subsequent delivery to 
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the lysosome (Futter et al., 1996, Lakadamyali et al., 2006, Puertollano 2005, Razi 
and Futter 2006).  In this way, phosphotyrosine-mediated recruitment of TOM1-L1 
to the activated EGFR on the plasma membrane not only triggers internalization from 
the surface via clathrin-coated vesicles but also primes TOM1-L1 to stay onto the 
early endosome for subsequent interaction with the sorting machinery for efficient 
segregation of EGFR into the MVB.  Further experiments are needed to examine this 
hypothesis. 
 
Other interesting issues to be resolved by future experiments include whether 
TOM1-L1 is also involved in the endocytosis of other RTKs and the relationship 
between TOM1-L1 and c-Cbl during EGFR endocytosis.  Since TOM1-L1 is also 
Tyr-phosphorylated upon stimulation by PDGF and FGF, it is conceivable that 
TOM1-L1 may be involved either directly or indirectly in the endocytosis of receptors 
for these ligands. The functional similarity of TOM1-L1 to Cbl in EGFR endocytosis 
and degradation remains to be examined. Cbl is known to be an E3 ubiquitinating 
enzyme for attaching multiple monoubiquitin moieties to the cytoplasmic domain of 
EGFR, a modification involved in endocytosis and subsequent sorting of internalized 
receptor to MVB for delivery to the lysosome for degradation (de Melker,  et al., 
2001, Citri and Yarden, 2006, Rubin et al., 2005).  Although Cbl is important in 
mediating EGFR endocytosis by multi-monoubiquitinating the cytoplasmic tail of 
EGFR, RNAi of individual ubiquitin-interacting proteins such as EPS15, ESP15R or 
Epsin has little effect on EGFR endocytosis (Huang et al., 2004), suggesting either 
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these proteins play redundant roles in recognizing ubiquitinated EGFR for 
endocytosis or Cbl mediates endocytosis by other means. In fact, the interaction of 
endocytosis-influencing TOM1-L1 with EGFR correlates strictly with receptor 
Tyr-phosphorylation rather than EGFR ubiquitination. EGFR reportedly remains 
ubiquitinated from 2 min up till 120 min after EGF stimulation (Shtiegman et al., 
2007, Stern et al., 2007) whereas TOM1-L1 is only transiently associated with 
Tyr-phosphorylated EGFR during the 2-5 min period following EGF stimulation. On 
this note, TOM1-L1 may act independently of Cbl for interaction with EGFR. A 
recent study has identified six distinct Lys (K) residues in the kinase domain of EGFR 
that are ubiquitinated in response to EGF stimulation.  Substitution of these Lys 
residues with Arg rendered the mutant EGFR defective in ubiquitination.  
Importantly, the ubiqutination-deficient mutant EGFR is endocytosed normally but 
severely impaired in degradation by the lysosome due to an arrest in the early 
endosome.  These results suggest that Cbl mediated ubiquitination of EGFR 
primarily influences endosomal sorting to the MVB/lysosome and another mechanism 
must account for Cbl participation in endocytosis (Huang et al., 2006).  Dual 
recognition of EGFR by TOM1-L1 and Cbl is highly likely to be important in 
mediating overlapping aspects of EGFR traffic in which TOM1-L1 acts primarily in 
endocytosis whereas Cbl-mediated ubiquitination acts mainly in the endosomal 




Chapter 10 Conclusion and Further Perspectives 
 
In this thesis, I have characterized and defined the cellular role of TOM1-L1. My data 
showed that TOM1-L1 and TOM1 have several characteristics in common: both 
contain an N-terminal VHS domain followed by a central GAT domain and a 
C-terminal region; both interact with clathrin and ubiquitin; and both are implicated in 
protein trafficking (Seykora et al., 2002, Yamakami et al., 2003, Seet et al., 2005). 
 
The most interesting and most different part of TOM1-L1 from other TOM1 family 
proteins (TOM1 and TOM1-L2) is at its C-terminus. Firstly, the C-terminus of 
TOM1-L1 contains a 460YEEI sequence which is the phosphorylation and binding site 
for SH2 domain of Src with a 421LPPLP motif for Src SH3 domain. This region also 
includes several tyrosine sites, which are not conserved in other TOM1 family 
proteins. Once TOM1-L1 is phosphorylated, these tyrosine sites create the binding 
sites for the SH2-domain containing signaling proteins Grb2 (392Y) and the p85 
subunit of PI3K (442Y) respectively (Seykora et al., 2002). Secondly, TOM1-L1 is 
transiently associated with activated EGFR during the very early events of EGF 
stimulation, which is dependent on the Tyr-phosphorylation of TOM1-L1 via Src/Fyn 
kinase activated by EGF and this interaction is likely to be mediated by Grb2 as a 
bridging protein. Thirdly, the 447FDLP450 motif of TOM1-L1 is essential for 
interacting with clathrin heavy chain. This interaction is also crucial for exogenous 
TOM1-L1 to rescue endocytosis of EGFR in TOM1-L1 knockdown cells. It suggests 
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that TOM1-L1 may be able to be transiently recuited to activated EGFR with clathrin 
and mediate the endocytic machinery for efficient segregation of EGFR into the 
endocytic vesicle. Fourthly, upon EGF stimulation, TOM1-L1 was recruited from the 
cytosol to the plasma membrane followed by its redistribution with EGFR into the 
early endosome. Fifthly, TOM1-L1 Y460F (Src SH2 binding mutant), Y392F (Grb2 
binding mutant) or its knockdown potently inhibits the endocytosis and degradation of 
activated EGF. It indicates that TOM1-L1 not only regulates the early step of EGFR 
endocytosis, but also may mediate the degradation of EGFR. Sixthly, TOM1-L1 
interacts with Hrs and STAM. This interaction is independent on each other, and 
over-expression of Hrs can recruit TOM1-L1 to early endosome. Moreover, 
knockdown of both TOM1-L1 and Hrs further delays EGFR degradation. Lastly, 
upon EGF stimulation, TOM1-L1 negatively regulates the activity of Ras and cell 
colony formation of A431. 
 
TOM1-L1 has 3 most interesting aspects that I want to highlight here. Firstly, 
TOM1-L1 is phosphorylated by growth factors (EGF, PDGF, and FGF) through 
Src/Fyn (SKF). Secondly, TOM1-L1 associates with clathrin. Thirdly, TOM1-L1 also 
interacts with ubiquitin, Hrs, STAM and TSG101 (Puertollano, 2005). The 
phosphorylation of TOM1-L1 has effects on both receptors signaling and endocytosis 
pathways. The interactions of TOM1-L1 with EGFR, Src/Fyn, Grb2, and PI3K p85 
subunit occur upon its phosphorylation. The PI3K-AKT signaling pathway regulates 
the growth and metabolism in response to insulin and growth factors, and is 
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frequently mutated in human cancers (Engelman et al., 2006).  Different tissue 
context causes different cellular responses to PI3K signaling pathway, and in many 
tissues defective PI3K signaling pathway contributes collectively to the complex 
metabolic defects associated with type-2 diabetes. Class IA PI3K is a heterodimer 
consisting of a p85 regulatory subunit and a p110 catalytic subunit. The p85 
regulatory subunit has both positive and negative effects on class IA PI3K signaling 
pathway. Under normal conditions, it is necessary for the stabilization of p110 subunit 
and activation of PI3K by the insulin receptor, whereas excess free p85 subunit 
negatively regulates class IA PI3K signaling pathway. It will be very interesting to 
investigate the functions of Tom1-L1 in PI3K signaling pathway via the interaction 
with p85 subunit upon EGF stimulation (Seykora et al., 2002).  
 
TOM1-L1 is recruited to membrane via interaction with Grb2 upon EGF stimulation. 
My data shows that TOM1-L1 regulates EGFR endocytosis through transient 
interaction with EGFR and recruiting clathrin to EGFR at the plasma membrane. The 
association of TOM1-L1 with clathrin is also crucial for the endocytosis of EGFR in 
response to EGF stimulation.  
 
Recently, it was reported that a single ubiquitin molecule binding to substrate is 
sufficient to direct lysosomal sorting as a signal tag, whereas in mammalian cells 
monoubiquin at multiple sites directs activated receptor tyrosine kinases to MVBs 
(Reggiori et al., 2001, Galan et al., 1997, Haglund et al., 2003, Mosesson et al., 2003, 
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Carter et al., 2004, Huang et al., 2006). Ubiquitination of the cytoplasmic tail of 
EGFR is important for mediating EGFR endocytosis. In addition, TOM1-L1 also 
interacts with ubiqutin (my data, Katoh et al., 2004, Puertollano, 2005.). So it will be 
interesting to investigate the function of TOM1-L1 on the endosomal sorting of 
EGFR.  
 
Hrs and STAM form the mammalian ESCRT-0 complex, which initiate the 
engagement of ubiquitinated receptor with the MVBs sorting machinery at the 
endosome through ubiquitin interacting motifs (UIMs), which is necessary for 
efficient sorting of ubiquitylated membrane proteins (Raiborg et al., 2002, Urbé et al., 
2003, Bache et al., 2003a, b, Mizuno et al., 2003). ESCRT-0 is associated and 
recruited to endosome though the FYVE domain of Hrs and the lipid PI3P, while it 
also recruits ESCRT-I to endosomes though the Pro-(Ser/Thr)-X-Pro motif of Hrs 
directly interacting with UEV domain of TSG101  (Clague and Urbé, 2003). Hrs and 
STAM also facilitate the sorting of EGFR to MVB and transport to lysosome where 
EGFR is degraded (Kanazawa et al., 2003). My data show that 20 mins after EGF 
stimulation, TOM1-L1 was dephosphorylated, and recruited to early endosomes with 
EGFR maybe via the interaction with ubiquitin, Hrs and STAM, and delays the 
degradation of EGFR. This will require further work to address the relationship of 
TOM1-L1 with Hrs, STAM and TSG101, and its function in subsequent sorting of 
internalized receptor to MVB for delivery to the lysosome and degradation (Citri and 
Yarden, 2006, Rubin et al., 2005).   
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So far most studies of TOM1-L1 are focused on its C-terminal. Unlike GGA, 
TOM1-L1 VHS domain cannot recruit ARF1 to TGN (trans-Golgi network )and 
interact with M6PR (mannose-6-phosphate receptor). Nor can its GAT domain bind to 
ARF. It is very interesting to investigate the functions of TOM1-L1 VHS and GAT 
domain. Work is being carried out to find more TOM1-L1 effectors by large scale 
immunoprecipitation screen with or without EGF stimulation. 
 
In conclusion, this thesis has addressed a role for TOM1-L1 as a regulated adaptor 
protein bridging activated EGFR with the endocytic machinery for endocytosis of 
activated EGFR. This study presents evidence that activatived EGF receptors 
phosphorylated TOM1-L1 through Src/Fyn, and phosphorylate-TOM1-L1 is recruited 
to EGFR with clathrin at plasma membrane. EGF receptor uptake and degradation are 
inhibited by interfering with TOM1-L1 function using mutant protein expression or 
RNA interference-mediated depletion of the protein. A novel clathrin-binding site is 
defined in the C-terminus of TOM1-L1, and the site is also shown to be important for 
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